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SUMMARY 
A non-coding RNA is a functional RNA molecule that is not translated into a protein. 
This class of molecules is involved in many cellular processes and includes highly 
abundant and functionally important RNAs such as transfer RNA (tRNA), ribosomal 
RNA (rRNA), as well as small interfering RNAs (siRNAs), microRNAs (miRNAs) and 
transcribed ultraconserved regions (T-UCRs). First of all, we investigate the 
specificity of each of the classes studied of two selected  non-coding RNA:  
Transcribed UltraConserved Region and microRNAs. second, we want to find 
whether these non-coding RNAs can be candidates as features for the selection of 
specific cancers, using statistical algorithms and bioinformatics tools. Third, we 
generate miRNA gene networks in normal and different cancer and leukemia. The 
term “ultraconserved” refer to genomic regions longer than 200 bp that are absolutely 
conserved (100% homology with no insertions or deletions) in human, mouse, and 
rat genomes. There are 481 T-UCRs. The reason for this extreme conservation 
remains a mystery;  T-UCRs may play a functional role in the ontogeny and 
phylogeny of mammals and other vertebrates. Genome-wide profiling revealed that 
UCRs are frequently located on overlapping exons in genes involved in RNA 
processing and can be found in introns or at fragile sites and in cancer-associated 
genomic regions.  We investigate the expression of T-UCRs in 374 normal samples 
from 46 different tissues, grouped by 16 systems. Moreover, we analyzed the tissue 
specificity of T-UCRs in cancers.  Tissue specific T-UCRs can differentiate cell types.  
We  then examine the expression of T-UCRs in human embryonic stem cells, 
induced pluripotent stem cells, and a series of differentiated cell types (trophoblast, 
embryoid bodies at 7 and 14 days of differentiation, definitive endoderm, and 
spontaneous differentiated monolayers).  One T-UCR in particular, uc.283 plus, is  
highly specific for embryonic and induced pluripotent stem cells, as confirmed by real 
time PCR (RT-PCR).  miRNAs are global regulators of protein output. Each miRNA 
has been studied for its single contribution to differential expression or to a compact 
viii 
 
predictive signature. Thus, we propose a study of miRNAs in cancer by applying a 
systems biology approach.  We study miRNA profiles in 4419 human samples (3312 
neoplastic, 1107 non-malignant), corresponding to 50 normal tissues  (grouped by 17 
systems) and 51 cancer types. We calculate tissue specificity and cancer type 
specificity, a small set of miRNAs were tissue-specific while many others were 
broadly expressed. Then we find whether non-coding RNAs can be candidates as 
features for the selection of specific cancers, using statistical algorithms and 
bioinformatics tools, as decision trees. Afterwards, we  build miRNA gene networks 
by using our very large expression miRNA database. The complexity of our 
expression database enable us to perform a detailed analysis of coordinated miRNA 
activities. We also build specialized miRNA networks for different solid tumors and 
leukemias.  Combining differential expression, genetic networks, DNA copy number 
alterations and other systems biology approaches we confirm or discovered, miRNAs 
with comprehensive roles in cancer. Normal tissues are represented by single 
complete miRNA networks. Cancers instead  show  separate and unlinked miRNA 
sub-networks. miRNAs independent from the general transcriptional program were 
often known as cancer-related. We validate our finding by in silico, in vitro and in vivo 
analysis. The target genes of these uncoordinated miRNA involve  in specific cancer-
related pathways. 
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1 INTRODUCTION 
 
1.1 Gene regulation and Post-transcriptional regulation  
 
Different cell types cells in a multicellular organism are capable of altering their 
patterns of gene expression in response to extracellular signals [1].  There are many 
steps in the pathway leading DNA to protein, and all of them can in principle be 
regulated. Mechanisms that underlie the control of gene expression are becoming 
increasingly well understood. There were  principally six steps at which eukaryote 
gene expression can be controlled: 1) transcriptional control; 2) RNA processing 
control; 3) RNA transport control; 4) post-transcriptional control; 5) translational 
control; 6) post-translational modification of the protein into its mature, functional form 
control.  We will focus on the mechanism of post-transcriptional regulation mediated 
by non-coding RNAs.  
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1.2 Non-Coding RNAs 
 
A non-coding RNA (ncRNA) is a functional RNA molecule that is not translated into a 
protein. This class of molecules is involved in many cellular processes and includes 
highly abundant and functionally important RNAs such as transfer RNA (tRNA) and 
ribosomal RNA (rRNA), as well as small interfering RNAs (siRNAs), microRNAs 
(miRNAs), PIWI-associated RNAs (piRNAs), small nucleolar RNAs (snoRNAs), 
promoter-associated RNAs (PARs), the recently identified telomere specific small 
RNAs (tel-sRNAs), long non-coding RNAs (lncRNAs)  and transcribed ultraconserved 
region ( T-UCRs). Moreover, this broad family of ncRNAs contributes to molecular 
alterations in a number of pathological conditions [2]. 
SiRNAs are small RNAs, 21–22 nucleotides (nt) long, produced by Dicer cleavage of 
complementary dsRNA duplexes. siRNAs form complexes with Argonaute proteins 
and are involved in gene regulation, transposon control and viral defense. 
PiRNAs, 24- 30 nt in length, are produced by a Dicer-independent mechanism, 
associate with Piwi-class Argonaute proteins and are principally restricted to the 
germline and bordering somatic cells. piRNAs are important for transposon control [3, 
4]  and regulate chromatin state [5]. A recent study suggests that an antisense RNA 
may trigger transcriptional silencing of a partner sense tumor suppressor gene; this 
effect occurs both in cis and in trans, and is Dicer-independent. The biochemical 
mediators of this silencing involve a Piwi-like protein, as their role in mammals is just 
beginning to be understood [6, 7]. In zebrafish, piRNAs have been implicated in germ 
cell maintenance and many of them were mapped to transposons suggesting that 
they play a role in silencing mechanisms of repetitive elements in vertebrates [8]. At 
the moment, no relations between piRNAs and diseases have yet been disclosed.  
SnoRNAs are small RNA molecules, approximately 60-300 nt long, which generally 
serve as guides for the catalytic modification of selected ribosomal RNAs [9, 10]. In 
vertebrates, most snoRNAs have been shown to reside in introns of protein coding 
host genes and are processed out of the excised introns.  snoRNAs can be divided 
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into two large groups, called box C/D snoRNAs and box H/ACA snoRNAs. Most of 
them are responsible for guiding the 2'-O-ribose methylations (box C/D snoRNAs) 
and pseudouridylations (box H/ACA snoRNAs) of ribosomal RNAs, transfer RNAs 
and small nuclear RNAs [11] . Many snoRNAs have been described as retrogenes 
[12]. Some snoRNA is processed to a small RNA that can function like a miRNA [13]. 
PARs encompass a suite of long and short RNAs, including promoter-associated 
small RNAs (PASRs) and transcriptional initiation RNAs, that overlap promoter 
regions. Their function is so far unknown but they possibly regulate transcription, as 
exogenous PASRs have been observed to reduce expression of genes with 
homologous promoter sequences [14].  
Tel-sRNAs in mouse embryonic stem cells are approximately 24 nucleotides in 
length, Dicer-independent, and 2'-O-methylated at the 3' terminus. The tel-sRNAs are 
asymmetric with specificity toward telomere G-rich strand, are evolutionarily 
conserved from protozoan to mammals and they may have a role in telomere 
maintenance [15]. 
LncRNAs are often longer than 2 kb in length with a coding potential of less than 100 
amino acids and the number of lncRNAs exceeds that of protein coding genes [16, 
17]. Recently, several studies identify that many lncRNAs are known to be retained in 
various sub-nuclear compartments [18] suggesting that such RNAs may have a 
potential function in the compartment where they are localized [19]. 
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Figure 1 Class of Non Coding RNAs. 
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1.3 Transcribed Ultraconserved Regions 
 
The term “ultraconserved” was originally proposed by Bejerano and colleagues to 
refer to genomic regions longer than 200 bp that are absolutely conserved (100% 
homology with no insertions or deletions) in human, mouse, and rat genomes [20]. 
Many of these elements possess tissue-specific enhancer activity [21-23] and others 
have been shown to associate with splicing regulators. Evolutionary conservation has 
become a powerful tool to identify functionally important regions in the human 
genome[24] . A greater percentage of the shorter elements show extreme 
conservation within mammals only and nearly 47% of ultraconserved elements in 
human have been localized to exons of genes involved in RNA processing or in the 
regulation of transcription and development [25]. 
The reason for this extreme conservation remains a mystery; but it suggests that 
UCRs may play a functional role in the ontogeny and phylogeny of mammals and 
other vertebrates. This idea is supported by findings that have identified a distal 
enhancer and an ultraconserved exon derived from a novel retroposon active more 
than 400 million years ago in lobe-finned fishes and terrestrial vertebrates, and 
maintained as active in the “living fossil” coelacanth. A recent study showed the 
concurrent presence of enhancer and transcript functions in non-exonic UCRs, and 
suggested they may be long ncRNAs [26]. 
Scientific interest in T-UCRs has significantly increased when they were shown to be 
involved in human carcinogenesis. Studies suggested that UCRs could contribute to 
the development of several types of malignancies [27]. Genome-wide profiling 
revealed that UCRs have distinct signatures in human leukemias and carcinomas 
[28] and are frequently located at fragile sites and in cancer associated genomic 
regions [29]. Recent clinical findings also suggest that T-UCR signatures can have 
prognostic value in high-risk neuroblastoma patients [30]. It has been shown that 
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some T-UCRs are deregulated in neuroblastomas, which could provide additional 
prognostic value in conjunction with MYC activity/amplification, currently used as a 
clinical prognostic indicator [31].  
 
 
1.4 MicroRNA biogenesis and functions 
 
miRNAs are a conserved class of non-coding RNAs that regulate the translation of 
mRNAs (messenger RNAs) by inhibiting ribosome function, decapping the 5’Cap 
structure, de-adenylating the poly(A) tail and degrading the target mRNAs [32]. 
MiRNAs are involved in mechanisms of gene regulation in both normal and diseased 
conditions and play a role during development, regulation of cell proliferation and 
apoptosis. The first miRNAs were identified in the nematode Caenorhabditis elegans, 
as small RNAs that interacted with the 3’ untranslated region (UTR) of the lin-14 
mRNA to inhibit its expression [33]. miRNAs are single-stranded RNAs of 19-24 
nucleotides (nt) in length generated through a complex maturation process. MiRNAs 
are transcribed by RNA polymerase II as molecules of variable length, the so-called 
primary-miRNA (pri-miRNA). The pri-miRNA is cleaved by Drosha - a RNAse III 
endonuclease that recognizes internal hairpin structures - and is then actively 
exported by Exportin-5 to the cytoplasm as a miRNA precursor (pre-miRNA) of 
approximately 70-120 nt. Once in the cytoplasm, the pre-miRNA is further digested 
by the enzyme Dicer (another Ribonuclease III), that yields a 21-22 nt long double-
stranded RNA (dsRNA) with 2- nt long overhangs [34]. The active single-stranded 
molecule(s) from this dsRNA associate(s) with several proteins to form the RNA-
induced silencing complex (RISC), which includes proteins of the Argonaute family 
[6]. miRNAs bind mostly to mRNA segments originating from the 3’ UTRs of genes 
[35] but the mechanism of translational repression is only partially understood.  
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1.5 microRNAs : oncogene and tumor suppressor roles 
 
The number of miRNAs in the human genome has been steadily increasing, and is 
now of 1600 (miRBase Release 19). Since their discovery, miRNAs quickly became 
the protagonists in the limelight of cancer research. By targeting and controlling the 
expression of mRNA, miRNAs can control highly complex signal-transduction 
pathways and other biological pathways. The biologic roles of miRNAs in cancer 
suggest a correlation with prognosis and therapeutic outcome. Dysregulation of 
physiologic microRNA (miR) activity has been shown to play an important role in 
tumor initiation and progression, the identification of differentially regulated miRNAs 
in cancer suggested a functional involvement in carcinogenesis, assigning them at 
times roles as tumor suppressors or as oncogenes.  
Those miRNAs whose expression is increased in tumors may be considered as 
oncogenes - also called “oncomiRs” - which promote tumor development by inhibiting 
tumor suppressor genes and/or genes controlling cell differentiation or apoptosis. 
The miR-17-92 cluster is a miRNA polycistron located at chromosome 13q31, a 
genomic locus that is amplified in lung cancer and several kinds of lymphoma, 
including diffuse large B-cell lymphoma. This cluster has been found to be regulated 
by c-Myc, an important transcription factor that is over-expressed in many human 
cancers . 
Microarray analysis revealed that these miRNAs may act as anti-apoptotic factors in 
human malignant disease. In several types of lymphomas, including Burkitt's 
lymphoma, the expression of miR-155 is increased. Furthermore, miR-155 is located 
in the only phylogenetically-conserved region of the BIC (B-cell receptor inducible) 
gene, suggesting that miR-155 may be responsible for BIC’s oncogenic activity [36]. 
Conversely, under-expressed miRNAs in cancers, such as some members of the let-
7 family, may function as tumor suppressor genes by regulating oncogenes and/or 
genes that control cell differentiation or apoptosis. Studies indicate that the RAS 
oncogene is a direct target of let-7, which negatively regulates RAS by pairing to its 
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3′ UTR for translational repression. Some recent studies have focused on microRNA-
binding site polymorphisms. Let-7 microRNA-binding site polymorphisms in the 
KRAS 3' UTR have been associated with reduced survival in oral cancers [37]. Other 
miRNAs that play a potential role as tumor suppressors include miR-15 and miR-16, 
which induce apoptosis by targeting anti-apoptotic gene BCL-2 (B-cell lymphoma 2) 
mRNA [38], MCL1 (myeloid cell leukemia sequence 1), CCND1 (cyclin D1), and 
WNT3A (wingless-type MMTV integration site family, member 3A) [39].  
MiRNAs are also involved in advanced stages of tumor progression, stressing their 
roles as metastasis activators or suppressors [40]. 
 
 
Figure 2 Schematic overview of microRNA processing and functional roles in cancer.  
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1.6 microRNAs signatures in solid cancers and leukemia 
 
The identification of differentially regulated miRNAs in cancer suggested a functional 
involvement in carcinogenesis, assigning them at times roles as tumor suppressors 
or as oncogenes. Such involvement exerts different effects based on the identity of 
the regulated target genes within the affected tissues. To date, several studies have 
addressed the different roles of miRNA in cancer establishment and progression. 
There are many relevant discoveries for each one of the major human solid cancer 
types. Table A1 is an overview of prominent miRNAs associated to solid cancers. 
Lung cancer is one of the first solid tumors in which microRNA expression patterns 
have been studied extensively. Lebanony et al. developed a diagnostic assay based 
on miR-205 expression that can distinguish squamous from adenocarcinoma non-
small-cell lung cancer (NSCLCs), with high sensitivity and specificity [41]. 
Knockdown of miR-31 represses lung adenocarcinomas cell clonal growth and in 
vivo tumourigenicity, via LATS2 and PPP2R2A, two protein regulating tumor growth 
[42]. miR-21 was found to drive lung tumorigenesis through inhibition of negative 
regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis. Let-7 was found 
to play the opposite role, acting as a tumor suppressor, partially through functional 
targeting of RAS, HMAG2 [43] and MYC [44]. Furthermore, reduced let-7 gene 
expression in NSCLC patients was correlated with poor prognosis [45, 46]; and a 
SNP in a let-7 complementary site in the KRAS 3′ UTR region increased NSCLC risk 
[47]. Pancreatic cancer (PC) is a highly aggressive malignancy with worst prognosis. 
The first approach used for identification of miRNA was the expression profiling of 
human specimens pancreatic adenocarcinoma paired normal pancreas, chronic 
pancreatitis and pancreatic cancer cell lines. Several studies have recently shown 
the deregulation of miRNA expression in PC tumor tissues using miRNA array 
technology and real-time PCR analysis [48-50]. These works identified, through 
independent different studies, a group of miRNAs up-regulated that increase 
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proliferation, tumorigenesis and invasion: miR-21 [51], miR-155 [52], miR-27a [53], 
miR-210 [54] ,miR-221/222 [50] and miR-196a-2 and miR-10b, that also may be 
negative survival predictor [49, 55]. On the other hand, there is a group of microRNA 
down-regulated having the opposite role: miR-146a [56], miR-20a [57], miR-96 [58] 
and miR-375 [49]. Aberrant expression of this set of miRNAs were independently 
associated with reduced survival. In plasma and in serum of patient with PC 
microRNAs has been suggested as a novel noninvasive approach of prognostic 
biomarkers [59, 60]. Iorio et al [61] reported the first 13 miRNA expression signature 
in breast cancer that was able to precisely discriminate between normal and tumor 
tissue. MicroRNA expression has also been shown to relate to some histopathologic 
features of breast carcinoma, such as estrogen receptor (ER) and progesterone 
receptor expression, grade and stage, and presence of invasion. Studies have been 
undertaken to investigate the correlation between microRNA expression and the 
classification in different subtypes of breast cancer. Among the differentially 
expressed and consistently deregulated miRNAs in breast cancer, miR-10b, miR-
125b, and miR-145 are down-regulated, while miR-21 and miR-155 are up-regulated 
which indicates their tumor suppressor or oncogenic roles, respectively. miR-21 is 
associated with advanced clinical stage, lymph node metastasis, and poor patient 
prognosis in breast cancer [62, 63]. miR-21 is known for regulation of cell survival 
and proliferation through direct targeting of tumor suppressor genes like PTEN, 
PDCD4 and TPM1. Iorio et al [61] reported the first 13 miRNA expression signature 
in breast cancer that was able to precisely discriminate between normal and tumor 
tissue. MicroRNA expression has also been shown to relate to some histopathologic 
features of breast carcinoma, such as estrogen receptor (ER) and progesterone 
receptor expression, grade and stage, and presence of invasion. Studies have been 
undertaken to investigate the correlation between microRNA expression and the 
classification in different subtypes of breast cancer. Among the differentially 
expressed and consistently deregulated miRNAs in breast cancer, miR-10b, miR-
125b, and miR-145 are down-regulated, while miR-21 and miR-155 are up-regulated 
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which indicates their tumor suppressor or oncogenic roles, respectively. miR-21 is 
associated with advanced clinical stage, lymph node metastasis, and poor patient 
prognosis in breast cancer [62, 63]. miR-21 is known for regulation of cell survival 
and proliferation through direct targeting of tumor suppressor genes like PTEN, 
PDCD4 and TPM1. Next generation sequencing experiment proposed by Farazi et 
al. presented a comparative analysis of miRNA read frequencies from different 
histological subtypes of breast cancer (normal breast samples, most non-invasive 
ductal carcinoma in situ and invasive carcinomas) by deep sequencing. They showed 
and confirmed the increment of level of miR-21 and multiple decreased miRNA 
families, including miR-98/let-7 [64]. Afterward, Volinia et al. identified nine-microRNA 
that differentiated invasive from in situ ductal carcinoma: let-7d, miR-210, and -221 
were down-regulated in the in situ and up-regulated in the invasive transition. miR-
210 had also a prognostic meaning for overall survival and time to metastasis [65]. 
MiRNA signatures obtained from different histotypes of ovarian carcinomas (serous, 
endometrioid, clear cell, and mixed) uncovered several miRNAs which appear to be 
specific to the histotypes compared to the normal tissues. In endometrioid tumors, 
the four most significantly up-regulated miRs include miR-200a, miR-200b, miR-200c 
and miR-141 which were also present in other types of ovarian cancer [66]. In 
addition, miR-21, overexpressed in several solid tumors, where it exerts anti-
apoptotic effect, was also found to be highly up-regulated. Alternatively, down 
modulation of microRNAs such as miR-222, which is known to target c-Kit, has been 
observed in endometrioid tumors. C-Kit is involved in cancer and is down-regulated 
in folate deficient conditions. Aberrant expression of several miRs: miR-214, miR-
199a*, miR-200a, and miR-100 have been detected in a near or over half of ovarian 
cancers, especially in late-stage and high-grade tumors. Hepatocellular carcinomas 
(HCCs) may have a distinct miRNA expression fingerprint according to malignancy, 
risk factors, and oncogene/tumor suppressor gene alterations. Dissecting these 
relationships provides a new hypothesis to understand the functional impact of 
miRNA deregulation in liver tumorigenesis and the promising use of miRNAs as 
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diagnostic markers. Ladeiro et al. [67] analyzed the expression levels of 250 miRNAs 
in 46 benign and malignant hepatocellular tumors and compared to those of 4 normal 
liver samples with qRT-PCR. miRNAs associated with genetic and clinical 
characteristics were validated in a second series of 43 liver tumor samples and 16 
non-tumor samples. Their study identified and validated miR-224 overexpression in 
all tumors and miR-200c, miR-200, miR-21, miR-224, miR-10b, and miR-222 specific 
deregulated in benign or malignant tumors. Lately, Pineau et al. identified a set of 12 
miRNAs linked to disease progression and demonstrated that the over-expression of 
miR-221 was protumorigenic in vivo, stimulated growth of tumorigenic murine hepatic 
progenitor cells [68]. Altered expression of microRNAs have a functional role in the 
initiation and progression of colon cancer. Schetter et al., in one of the first studies 
with a large cohort of colon adenocarcinoma patients samples, identified thirty-seven 
microRNAs differentially expressed in tumors from the test cohort. Again, high levels 
of miR-21 was associated with poor survival and poor therapeutic outcome [69]. 
Lately, in a subsequent study they found systematic changes in eight inflammatory 
gene ( IL-8, IL-23a, IL-1a, IL-1b, IL-17a, INFγ , IL-6 and FOXP3 ) expression in colon 
tumors; that was associated with miR-21 expression. They suggested that the 
combination of inflammatory genes and miR-21 expression can be a better predictor 
of prognosis [70].  
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Figure 3 The most important miRNAs differentially regulated in solid cancers. miRNAs 
are either red (over-expressed) or green (down-regulated). 
 
The role of miRNA in cancer was first discovered in leukemia. Calin et al. [71] 
reported evidence for the role of miRNAs in the pathogenesis of CLL deletions and/or 
down-regulation of miR-15a and miR-16-1 at chromosome 13q14 were associated 
with CLL. Afterward, a study demonstrated that this cluster can regulate the 
expression of the BCL-2 (B-cell lymphoma 2) oncogene [72]. Other relevant 
alterations of miRNAs in CLL include down-regulation of miR-181a, let-7a, miR-30d, 
miR-150 and miR-92 , and over-expression of miR-155. In Table A2 are resumed the 
principal miRNAs associated to leukemia and hematologic diseases. miR-155 and 
miR17-92 cluster are commonly amplified in B-cell lymphoma patients and together 
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were among the earliest ncRNAs to be linked cancer. miRNA expression signatures 
have revealed differences between acute lymphoblastic leukemia (ALL) and acute 
myeloid leukemia (AML) [73]. Specific miRNA were correlated to karyotype 
alterations in AML , that have reported microRNA signatures associated with 
cytogenetics and prognosis of AML, with molecular abnormalities like translocations  
t(11q23), trisomy 8 and FLT3 (receptor tyrosine kinase) internal tandem duplication 
(ITD) mutations. Down-regulation of miR-221 and miR-222 was observed in AML 
[74].  
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1.7 microRNA target genes 
The explication of the miRNA activity is strictly related to mRNA targets. In order to 
predict miRNA target interactions, many computational approaches have been 
developed. The topic of these software predicts biological targets of miRNAs by 
searching for the presence of conserved 8mer and 7mer sites that match the seed 
region of each miRNA [75]. Experimental evidence were needed to validate the 
target prediction. Below  there are list some of the published and most used 
algorithms. 
TargetScan [76] was one of the first RNA fold program and a total free binding 
energy is calculated with the RNAeval algorithm. The free energy is converted to a 
zscore and predictions in each organism are ranked. The algorithm takes three 
parameters: one that defines the relation between the binding energy and the z-
score, a z-score cut-off, and a ranking cutoff value. As an option, nonconserved sites 
are also predicted . TargetScanHuman considers matches to annotated human 
UTRs and their orthologs, as defined by UCSC whole-genome alignments. 
Conserved targeting has also been detected within open reading frames (ORFs). 
“TargetScan” is one of the earliest published algorithms, it has maintained its role as 
a gold standard in many experiments. 
RNA22  [77] is a pattern-based algorithm for the discovery of microRNA target sites 
and the corresponding heteroduplexes Statistical significance of each individual motif 
is assessed by training a second-order Markov chain. The key idea of rna22 is that 
the reverse complement of any salient sequence features that one can identify in 
mature microRNA sequences (using pattern discovery techniques) should allow one 
to identify candidate microRNA target sites in a sequence of interest: once a 
candidate microRNA target site has been located, the targeting microRNA can be 
identified with the help of any of several algorithms able to compute RNA:RNA 
heteroduplexes. 
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miRanda  miR-SVR [78] are incorporated in microRNA.org , as a target searcher tool. 
mirSVR is a machine learning method for ranking microRNA target sites by a down-
regulation score. The algorithm trains a regression model on sequence and 
contextual features extracted from miRanda-predicted target sites. It uses the same 
basic principles of  TargetScan, but there are some difference in the calculation of 
the score. 
PITA  [79] is an algorithm, published in 2007 by Kertesz and coworkers, mainly 
based on secondary RNA structure. This application can be run as a standalone 
version or as a webserver.  The main assumption is based on the fact that the mRNA 
structure plays a role in target recognition by thermodynamically promoting or 
disfavoring the interaction, using complementarity analysis within seed regions 
(single mismatch or G:U wobble pairing can be allowed) and then compares the free 
energy gained from the formation of the miRNA-target duplex and the energetic cost 
of unpairing the target to make it accessible to the miRNA. 
PicTar [80] searches for nearly but not fully complementary regions of conservative 
3’UTRs and then calculates the free energy of created duplexes. Each result is 
scored using Hidden-Markov Model . miRNAs with multiple alignments are favored., 
It was the first method that considered a parallel expression on the cellular level or an 
action in a common biological pathways of a miRNA and transcript, co-expressed 
miRNAs are more likely to target the same mRNAs. According to the authors, adding 
probabilistic knowledge about co-expression significantly increases specificity. It uses 
sequence alignment to eight vertebrate species to eliminate false positive results and 
it scores the candidate genes of each species separately to create a combined score 
for a gene. 
Diana microT [81, 82]  is an algorithm based on the use of uses a 38nt-long frame 
that is moved along 3’UTR , searching   for sites with canonical central bulge and it 
requires 7, 8 or 9 nt–long complementarity in 5’ region of miRNA. 6 nt-long matches 
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within seed region or with one wobble pairing are also considered while enhanced by 
additional base pairing in 3’ region of miRNA. DIANA-mciroT use conservative 
alignment for scoring but also considers non-conservative sites. It gives unique 
signal-to-noise ratio (SNR) which is a ratio between a total of predicted targets by 
single miRNA in searched 3’UTR and a total of predicted targets by artificial miRNA 
with randomized sequence in searched 3’UTR. Another tool of the same platform is 
DIANA-mirPath [83], that is able to integrate human and mouse microRNAs in known 
cellular pathways. 
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1.8 High-throughput technology 
 
One of the first high-throughput technology was microarray. Microarray technology 
evolved from Southern blotting, where fragmented DNA is attached to a substrate 
and then probed with a known DNA sequence. A DNA microarray is used in 
molecular biology and medicine, it consists of a collection of microscopic DNA spots 
attached to a solid surface. Scientists use DNA microarrays to measure the 
expression levels of large numbers of genes simultaneously or to genotype multiple 
regions of a genome. Each DNA spot contains picomoles (10−12 moles) of a specific 
DNA sequence, known as probes (or reporters or oligos). These can be a short 
section of a gene or other DNA element that are used to hybridize a cDNA or cRNA 
(also called anti-sense RNA) sample (called target) under high-stringency conditions. 
Probe-target hybridization is usually detected and quantified by detection of 
fluorophore-, silver-, or chemiluminescence-labeled targets to determine relative 
abundance of nucleic acid sequences in the target. 
The core principle behind microarrays is hybridization between two DNA strands, the 
property of complementary nucleic acid sequences to specifically pair with each other 
by forming hydrogen bonds between complementary nucleotide base pairs. A high 
number of complementary base pairs in a nucleotide sequence means tighter non-
covalent bonding between the two strands. After washing off of non-specific bonding 
sequences, only strongly paired strands will remain hybridized. Fluorescently labeled 
target sequences that bind to a probe sequence generate a signal that depends on 
the hybridization conditions (such as temperature), and washing after hybridization. 
Total strength of the signal, from a spot (feature), depends upon the amount of target 
sample binding to the probes present on that spot. Microarrays use relative 
quantization in which the intensity of a feature is compared to the intensity of the 
same feature under a different condition, and the identity of the feature is known by 
its position. Many types of arrays exist and the broadest distinction is whether they 
are spatially arranged on a surface or on coded beads:  traditional solid-phase array 
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is a collection of orderly microscopic "spots", called features, each with a thousands 
of identical and specific probes attached to a solid surface, such as glass, plastic or 
silicon biochip (commonly known as a genome chip, DNA chip or gene array). 
Thousands of these features can be placed in known locations on a single DNA 
microarray.  The alternative bead array is a collection of microscopic polystyrene 
beads, each with a specific probe and a ratio of two or more dyes, which do not 
interfere with the fluorescent dyes used on the target sequence. 
DNA microarrays can be used to detect DNA (as in comparative genomic 
hybridization), or detect RNA (most commonly as cDNA after reverse transcription) 
that may or may not be translated into proteins. There are many different types of 
microarray-based assays: 
     
- DNA microarrays for transcriptomics research 
- DNA tiling arrays for ChIP on chip experiments 
- DNA microarrays for genotyping  
- DNA microarrays for resequencing 
- Protein microarrays to detect protein-protein interactions 
- Antibody-Based Protein Array for protein quantification 
- Chromatin Immunoprecipitation Assay (ChIP) 
- Single Nucleotide Polymorphism (SNP) array 
- Tissue Microarray. 
  
Microarray Expression Analysis: In this experimental setup, the cDNA derived from 
the mRNA of known genes is immobilized. The sample has genes from the normal as 
well as the diseased tissues, or from  cells  in differentiation. Spots with more 
intensity are obtained for diseased tissue gene if the gene is over expressed in the 
diseased condition. This expression pattern is then compared to the expression 
pattern of a gene differentially expressed, in this context microarray analysis could be 
used as a “phenotyping tool”. Furthermore, It can be useful  for the determination of 
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molecular pathways: analysis of gene-expression changes in biological systems that 
model disease might lead to the identification of pathways that play a crucial role in 
disease pathogenesis. Another analysis is represented by the global assessment of 
drug effects in appropriate cell, or animal model systems or patient samples. Besides 
steady-state effects, it is also possible to determine the kinetics of the expression 
response as different genes respond in a time-dependent fashion at different 
intervals following a perturbation, or it is possible determinate comprehensively how 
cells or tissues respond to a particular drug might make it possible to  predict  either 
efficacy or adverse effects to a drug, eventually providing  the presence of 
biomarkers that can be used to readily monitor drug efficacies as well as side effects 
and disease progression. In order to identify genomic copy number variations (CNV) 
across the whole genome at a different  resolution levels, it is possible use an array, 
named Comparative genomic hybridization array ( aCGH). 
In order to analyze miRNAs profiling, many microarray based on miRNA were 
developed too. There are many platforms that can perform miRNA array profiling, for 
example Agilent, Affymetrix, Exiqon, Illumina, etc.  
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Figure 4 Graphic result of the research of "microarray" term per year in citation ( 
Figure is obtained using information from  
http://www.ncbi.nlm.nih.gov/pubmed/?term=microarray) 
 
 
The number of scientific articles that have used microarray technology had 
exponentially grew up in the last fifteen years (Figure 4). The huge amount of 
information obtained by this technology are available online for all user, there are 
many public database for microarray data. The database meant to be central 
repositories and the most known are: 
 
- GEO- Gene expression omnibus (http://www.ncbi.nlm.nih.gov/geo/): 
It uses the annotation standard Minimum Information About a 
Microarray Experiment (MIAME) and serves as a public repository for a wide range of 
high-throughput experimental data. These data include single and dual channel 
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microarray-based experiments, measuring the abundance of mRNA, genomic DNA 
and protein molecules. Data from non-array-based high-throughput functional 
genomics and proteomics technologies are also archived. Several tools are provided 
to assist with the visualization and exploration of GEO data, including hierarchical 
cluster heat maps and searchable individual gene expression profiles. 
 
 
Figure 5 Screenshot of GEO interface (http://www.ncbi.nlm.nih.gov/geo/). 
 
 
- ArrayExpress Archive (http://www.ebi.ac.uk/arrayexpress/): 
It uses the annotation standard  MIAME and the associated 
XML data exchange format Microarray Gene Expression Markup Language (MAGE-
ML) and it is designed to store well annotated data in a structured way. Consists of 
the database itself, data submissions in MAGE-ML format or via an online 
submission tool MIAMExpress, online database query interface, and the Expression 
Profiler online analysis tool. 
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Figure 6 ArrayExpress interface from EMBL-EBI (http://www.ebi.ac.uk/arrayexpress/) 
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1.9 Regulatory networks 
 
A biological networks use a directed graph representation in an effort to model the 
way that proteins and other biological molecules are involved in gene expression. A 
gene regulatory network (GRN) is a collection of DNA segments in a cell which 
interact with each other (indirectly through their RNA and protein expression 
products) and with other substances in the cell, thereby governing the rates at which 
genes in the network are transcribed into RNA. 
A typical gene regulatory network might be defined like this: the nodes of the network 
are proteins, their corresponding mRNAs, or protein/protein complexes. Edges  
between nodes represent individual molecular reactions, the protein/protein or 
protein/mRNA interactions through which the products of one gene affect those of 
another. These interactions can be inductive, with an increase in the concentration of 
one leading to an increase in the other, or inhibitory, with an increase in one leading 
to a decrease in the other. A series of edges indicates a chain of such dependences, 
with cycles corresponding to feedback loops. The network structure is an abstraction 
of the system's chemical dynamics, describing the manifold ways in which one 
substance affects all the others to which it is connected. In one instance, such GRNs 
can be inferred from the biological literature on a given system and represent a 
distillation of the collective knowledge about a set of related biochemical reactions. 
Genes can be viewed as nodes in the network, with input being proteins such as 
transcription factors, and outputs being the level of gene expression. The node itself 
can also be viewed as a function which can be obtained by combining basic functions 
upon the inputs (in the Boolean network described below these are Boolean 
functions, typically AND, OR, and NOT). These functions have been interpreted as 
performing a kind of information processing within the cell, which determines cellular 
behavior. The basic drivers within cells are concentrations of a macromolecule, which 
determine both spatial (location within the cell or tissue) and temporal (cell cycle or 
developmental stage) coordinates of the cell. The gene networks are only beginning 
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to be understood, and it is a next step for biology to attempt to deduce the functions 
for each gene "node", to help understand the behavior of the system in increasing 
levels of complexity, from gene to signaling pathway, cell or tissue/organ level 
(“systems biology”). Mathematical models of GRNs have been developed to capture 
the behavior of a system, and in some cases generate predictions corresponding to 
experimental observations. We used a Bayesian approach. 
Bayesian networks (BNs) or Bayes nets for short, are considered a kind of 
probabilistic graphical models. These graphical structures are used to represent 
knowledge about an uncertain domain. In particular, each node in the graph 
represents a random variable, while the edges between the nodes represent 
probabilistic dependencies among the corresponding random variables. Using known 
statistical and computational methods the conditional dependencies in the graph are 
estimated; so it is possible combine principles from graph theory, probability theory, 
computer science, and statistics. 
Graphical models with undirected edges are generally called Markov random fields or 
Markov networks. These networks provide a simple definition of independence 
between any two distinct nodes. BNs correspond to another graphical models 
structure known as a directed acyclic graph. BNs are both mathematically rigorous 
and intuitively understandable. They enable an effective representation and  
computation of the joint probability distribution over a set of random variables. 
The structure of a directed acyclic graph is defined by two sets: the set of nodes 
(vertices) and the set of directed edges. 
The nodes represent random variables and are drawn as circles labeled by the 
variable names. The edges represent direct dependence among the variables and 
are drawn by arrows between nodes. In particular, an edge from node 1 to node 2 
represents a statistical dependence between the corresponding variables [84, 85]. 
Thus, the arrow indicates that a value taken by variable depends (influences) on the 
value taken by another variable. 
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2 THESIS OBJECTIVES 
 
The aim of the thesis was to answer the question whether the non-coding RNAs 
expression data can be used for a classification of the normal tissues and of the 
several cancers using system biology approaches. Therefore we want to investigate 
the specificity of each of the classes studied of non-coding RNA, as Transcribed 
UltraConserved Region and microRNAs. Furthermore, we want to find whether non-
coding RNAs can be candidates as features for the selection of specific cancers, 
using statistical algorithms and bioinformatics tools. Then, we decided to infer 
Bayesian networks for miRNAs in normal and cancer samples to identify the relations 
between their expression and pathological role. In order to prove our expression data 
analysis  and the networks of cancers, we want to apply: in silico validation using 
several bionformatic approaches on data available in our and public database, 
experimental validations using biologic and molecular technics of laboratory. We 
expect our results to show evidences which sustain the use of non-coding RNAs 
expression data for the characterization of cancers and eventually the identification of 
new markers of cellular subpopulations of cancer. 
 
Consequently, the aims of the thesis were : 
 
i.  Calculate tissue specificity of the non-coding RNAs in normal samples, using our 
large expression database; 
ii. Classification of solid cancer by non-coding RNAs; 
iii. Elaboration of the miRNA bayesian networks of cancers; 
iv. In silico, in vitro and in vivo validation. 
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3 THE TISSUE SPECIFICTY OF T-UCRs AND miRNAs 
 
3.1 Material and Methods   
 
Microarray analysis was performed miRNA microarray assay on a CodeLink platform. 
The miRNA array consists of 4,104 probes printed in duplicate. This array can 
simultaneously profile more than 1,500 mature miRNAs and their corresponding 
precursor [86]. The Ohio State University Comprehensive Cancer Center custom 
microarray was used for T-UCR expression profiling following previously published 
protocols. For each UCR two 40-mer probes were designed, one corresponding to 
the sense genomic sequence (named “+” or “plus”) and the other to the 
complementary sequence (named “+A” or “minus”). Each oligo was printed in 
duplicate in two different slide locations, and therefore quadruplicate numerical 
values were available for analysis. Briefly, 5 micrograms of total RNA were used for 
hybridization of miRNA microarray chips. These chips contain gene-specific 
oligonucleotide probes, spotted by contacting technologies and covalently attached 
to a polymeric matrix. The microarrays were hybridized in 6X SSPE (0.9 M NaCl/60 
mM NaH2PO4 ·H2O/8 mM EDTA, pH 7.4)/30% formamide at 25°C for 18 hrs, 
washed in 0.75X TNT (Tris·HCl/ NaCl/ Tween 20) at 37°C for 40 minutes, and 
processed by using a method of detection of the biotin-containing transcripts by 
streptavidin-Alexa647 conjugate. Processed slides were scanned using a microarray 
scanner (Axon), with the laser set to 635 nm, at fixed PMT setting, and a scan 
resolution of 10 mm. Microarray images were analyzed by using GenePix Pro and 
post-processing was performed [87] . Briefly, average values of the replicate spots of 
each miRNA were background-subtracted and subject to further analysis. miRNAs 
were retained when present in at least 20% of samples and when at least 20% of the 
miRNA had fold change of more than 1.5 from the gene median. Absent calls were 
thresholded prior to normalization and statistical analysis. Normalization was 
performed by using the quantiles method. MicroRNA nomenclature was according to 
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the microRNA database at Sanger Center [88] . The expression data analyzed in this 
study can be accessed at the NCBI Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo) under accession nos. GSE8126 and GSE7055, 
GSE17155, GSE3467, GSE7828, GSE6857, GSE16654, and GSE14936, and at 
ArrayExpress (www.ebi.ac.uk/microarray-as/ae) under accession nos. E-TABM-866, 
E-TABM-664 E-TABM-762 and E-TABM-763, E-TABM-508, E-TABM-429, E-TABM-
434, E-TABM-405, E-TABM-343, E-TABM-41 and E-TABM-42, E-TABM-48, E-
TABM-22 , E-TABM-23, ETABM-46, E-TABM-47, E-TABM-49, and E-TABM-50, and 
E-MEXP-1796, E-TABM-37, E-TABM-341, E-TABM-969 and E-TABM-970 for normal 
tissues, E-TABM-971 for breast cancer, E-TABM-972 and E-TABM-974 for acute 
myeloid leukemia, E-TABM-973 for chronic lymphocytic leukemia and E-TABM-975 
for ovarian cancer.  
 
 
3.1.1 Data analysis 
 
We have developed an SQL miRNA internal database that contained the data 
retrieved from a large number of different experiments performed with miRNA 
microarray. Bad spots were removed. Non-Expressed spots were averaged for each 
gpr files (chip). For each mature miRNA, we computed the geometric mean of its 
multiple reporters in the chip. A NaN value was assigned to miRNAs with more than 
50% of corrupted spots, as reported by the GenePix image analysis software. All the 
results were log2-transformed. The Normalization was performed by using the 
quantiles normalization, as implemented in Bioconductor "affy" package [89]. 
Quantile normalization is a non-parametric procedure and the algorithm mapped 
every value on any one chip to the corresponding quantile of the standard 
distribution. BRB Arraytools was used to perform t-test over 2-classes experiments of 
F-tests over multiple classes. 
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3.1.2 Calculation of Information Content 
 
First, all samples were classified according to their organ-, tissue- and celltype; then 
the normal samples were grouped in specific systems and the disease samples in 
specific pathological states. To assess the specificity of miRNA expression across 
groups, we needed to estimate what fraction of the total, for a given miRNA belonged 
to each single group. We used the procedure described in the first miRNA expression 
atlas [90], with the only exception that we called Em,t the value of miRNA m in the 
group t referred to as "mean expression value” (subtracted of the background value, 
100). From here onwards, we essentially proceeded as the reference, therefore: To 
allow for comparisons between tissue types, we first normalized the counts in each 
tissue type t: 
 
Fm,t = Em,t / Σm' Em',t 
 
If a miRNA m is expressed with high specificity in tissue type t, then the value Fm,t is 
large (close to 1) not only relative to other miRNAs m' m in the same tissue type t (or 
column of F), but also relative to the same miRNA m in other tissue types t'≠ t. It is 
then natural to normalize the lines of F as: 
 
Gm,t = Fm,t / Σt' Fm,t' 
 
Each line m of G contains a distribution of normalized frequencies of miRNA m 
across samples. When Gm,t* is close to 1 in tissue t*, we may infer that miRNA m is 
specifically expressed in tissue type t*, meaning that a large fraction of clones in t* 
and much smaller fractions of clones in other t≠ t* correspond to miRNA m. We use 
the information-theoretic concept of "information content" to quantify how strongly 
biased the distribution of Gm,t is for a given m: 
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sm = log2(number of tissue types) + t ΣGm,t log2(Gm,t). 
 
The specificity score varies between 0, when the expression level of the miRNA m is 
the same across all tissues, and log2 of the number of tissue types, when only one 
tissue expresses the miRNA. To minimize artifacts from miRNAs or tissues with very 
small expression levels, we considered only miRNAs with a total expression value 
above 10 times the number of normal tissues and above 100 times the number of 
cancer types; with a minimal expression value (after background subtraction) of 100. 
For the calculation of overall specificity, we thus included 130 and 133 different 
mature miRNAs for normal tissues and cancer, respectively. Therefore, it is possible 
that we missed some specifically expressed miRNAs that in our data had either very 
low expression or were specific to tissues/diseases that we did not sample 
sufficiently. The same approach is used for the T-UCR information content.  
 
3.1.3 Decision Tree 
 
The expression matrix of T-UCRs values was used to infer an ultra-selection system 
using weka software [91]. First, for all the samples we have applied a supervised 
attribute filter to select attributes (in this case the T-UCRs expressions value). This 
process has selected 16 attributes; after we used the weka classifiers trees J48 graft 
-C 0.25 -M 2, in order to calculate how these attributes produce an accurate 
classification of the tissue selected. We used also JRip (RIPPER) algorithms. 
Classes were examined in increasing size and an initial set of rules for the class was 
generated using incremental reduced error JRip proceeds by treating all the 
examples of a particular judgment in the training data as a class, and finding a set of 
rules that cover all the members of that class. So, it proceeded to the next class and 
repeat the same, repeating this until all classes have been covered. J48 is an open 
source Java implementation of the C4.5 algorithm in the weka data mining tool. C4.5 
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builds decision trees from a set of training data, using the concept of information 
entropy. The training data is a set S = (s_1, s_2, ...) of already classified samples. 
Each sample s_i consists of a p-dimensional vector and the x_j represent attributes 
or features of the sample, as well as the class in which s_i falls. At each node of the 
tree, C4.5 chooses the attribute of the data that most effectively splits its set of 
samples into subsets enriched in one class or the other. The splitting criterion is the 
normalized information gain (difference in entropy). The attribute with the highest 
normalized information gain is chosen to make the decision. The C4.5 algorithm then 
recourses on the smaller sub-lists. All the samples in the list belong to the same 
class. When this happens, it simply creates a leaf node for the decision tree saying to 
choose that class. None of the features provide any information gain. In this case, 
C4.5 creates a decision node higher up the tree using the expected value of the 
class. Work flow of the information that we have used for performing analysis using 
weka software are in APPENDIX B. 
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3.2 miRNAs tissue specificity in normal and embryonic samples 
 
The first microRNA that we found specific for the embryonic cell types was the hsa-
miR-302: embryonic cell types, such as embryonic bodies, trophoblasts, endoderm, 
or other stem cells including induced pluripotent stem cells (iPS) also harbored high 
levels of this miRNA. In the figure 7,  after hsa-miR- 302, the most specific miRNAs 
were hsa-miR-338-5p, hsa-miR-323-3p, and hsa-miR-335, with presented highest 
expression in epidermis /nervous system, nervous system and breast respectively. 
All the values of the IC were listed in the Table A3. 
Hsa-miR-371-5p was here well represented in embryonic cell types, in particular 
there was a high hsa-miR-371-5p expression in embryoid bodies. Hsa-miR-129-3p is 
specific for nervous system in both datasets. We detected hsa-miR-142-5p in 
hematopoietic system and connective tissues. Hsa-miR-9, hsa-miR-128 and hsa-
miR-138 were expressed in nervous system. 
Nevertheless, the IC distributions were very similar: 25 miRNAs with IC higher than 
1.35 for the microarrays. The most notable IC was without doubt the  hsa-miR-
302a/b/c.  
33 
 
 
Figure 7. miRNA specificity in 50 normal tissues grouped by system. The tissue 
specificity was calculated by using the information content (IC), value expressed on y-
axis; each color represents a system. miR-302 cluster is the most representative for 
embryo tissues. 
 
Since hsa-miR- 302 expression only partially decreased throughout these stages of 
ES differentiation, its IC in embryonic  tissues was low (0.5). This variation might be 
due to the fact that we assayed different cell types of embryonic origin, in comparison 
to only ES cells. The miRNAs which had highest tissue specificity in embryos were: 
hsa-miR-211 in 14 day embryoid bodies (EBs), hsa-miR-10b, hsa-miR-218, hsa-miR-
122, and hsa-miR-148a in spontaneous differentiated monolayers, hsa-miR-138 and 
hsa-miR-338-3p in 7 day EBs, and hsa-miR-99a in trophoblast (Figure 8 and Table 
A4). 
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Figure 8 The specificity was calculated by using the information content (IC). The 
miRNA specificity during ES cell differentiation.  
  
35 
 
3.3 T-UCRs tissue specificity in normal and embryonic samples 
 
We used the same approach for check  the expression of the T-UCRs. We tested the 
expression in 374 samples from 46 types of normal tissue derived from 16 
histological groups. Tissue specificity was calculated using the information content 
(IC) as described previously in 3.1.2 Material and Methods section. For this profile we 
used data obtained with the OSUMC microarray platform, where there were 974 
different probes for putative T-UCRs in both genomic strands (sense, designated 
‘plus’ and antisense, designated ‘minus’). 
First, a wide analysis of expression showed that only a portion among the tested 
UCRs (224 out of 974) was expressed in human tissues (p-value < 0.05). Of these: 
48% were non-exonic, 26% possibly exonic and 26% exonic, thus reflecting 
previously published studies. Fifty-seven T-UCRs were bi-directionally transcribed 
(57 on 224) and their frequencies were: 37% non-exonic, 23% possibly exonic, and 
40% exonic  (Table A5).  
The most tissue specific T-UCRs were represented by a group of 13 T-UCRs, 
exclusively expressed in epidermis, with an IC value ranging from 3.23 to 1.70, 
composed of 67% non-exonic, 19% possibly exonic, and 14% exonic sequences 
(Figure 9 and Table A6 ). 
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Figure 9. T-UCR specificity in 46 normal tissues grouped by 16 systems. The tissue 
specificity was calculated by using the information content (IC), value expressed on y-
axis; different colors represents different systems.  
 
These T-UCRs were not located in the same genomic cluster. Another tissue-specific 
UCR was uc.450 plus, highly expressed in the central nervous system. This confirms 
previous data showing that uc.450 was expressed in the dorsal root ganglion and the 
neural tube [92]. In particular, researcher hypothesized an enhancer function for 
hs385, which fully includes uc.450. Interestingly, the opposite probe, uc.450 minus, 
was specific for the respiratory system. Uc.174 minus, located on the opposite strand 
of the MATR3 exon, was expressed only in the respiratory system and epidermis. 
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The placenta was characterized by the expression of uc.319 minus (intergenic), while 
uc.237 minus (intronic) was restricted to the gastrointestinal system. 
Two T-UCRs expressed both in liver and in the respiratory system were uc.43 minus 
(intronic, our probe is homologous to Mus Musculus CN668140 EST) uc.75 minus, 
located on the opposite strand of the last exon of ZEB2, and uc.42 plus (intronic). In 
addition, uc.417 minus was expressed in adipose tissue and in the gastrointestinal 
system. The only T-UCR specific for the embryo was uc.283 plus. This unique uc.283 
plus, a 277 nucleotide-long sequence located at chr10:50,604,757-50,605,033, was 
sufficient to discriminate between adult differentiated tissues and pluripotent stem 
cells (Figure 10).  
 
 
Figure 10 The spot represented the value of the probe uc.283plus , blue and cyan were 
plotted the ESC and IPS; black were the pool of normal adult differentiated cells.   
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Second, we found which were the T-UCR specific for  the stages of ES differentiation 
( Figure 11).  
 
 
Figure 11 The T-UCRs specificity during ES cell differentiation, seven different types of 
embryonic condition. The specificity was calculated by using the information content 
(IC). 
 
There were four T-UCRs expressed only in ESC and IPSC. We checked the 
enhancer activity using VISTA tool from Genome Browser track. Uc.204 minus, was 
located in a intergenic genomic area, identified by human element hs293, showed 
enhancer function ( for branchial arch, forebrain and midbrain). Uc.192 plus, located 
in intergenic position, hs217, showed an enhancer function (for forebrain and 
midbrain ). Moreover, in our data uc.192 plus highly expressed in IPS and in the 
second node of the decision tree, we noted that this over-expression can discriminate 
IPS from ESC (Figure 12).  
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Figure 12 Decision tree is obtained by analysis of the expression data. 
 
Uc.350 plus didn’t show enhancer function, it was located in intronic region of 
DACH1, a gene that encodes a chromatin-associated protein associated with other 
DNA-binding transcription factors regulating gene expression and cell fate 
determination during development. Uc.398 minus was intergenic and located in a 
CpG island (374 nucleotides), there were to EST homologous in Xenopus and Danio 
Rerio . 
For definitive endoderm the most representative T-UCR was uc.478 plus, but it was 
the unique  probe that cover two genome sequences on two different chromosome: 4 
and X, intronic/exon containing of Gria 2 (chr.4) and Gria 3 ( chr. X). There was a 
little cluster of UCRs for embryonic bodies : uc.257 plus (intronic) , uc.252 minus was 
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intronic and homologous to an EST of Petromyzon marinus , this EST was extracted 
by fertilized egg to completion of digestive tract retained in a library of Lamprey EST 
Embryo. Uc.133 minus was intronic and located in the RSRC1 gene. Uc.183 minus: 
intronic/exon containing FBXW11. Uc.347 minus was intergenic, while uc.372 plus is 
located to an intron of RALGAPA1.  Finally, uc.269 minus was present in definitive 
endoderm, ESC and IPSC; it was located in an intronic region of KIAA1608 and the 
respective hs314 has shown enhancer function for midbrain (mesencephalon) in 
VISTA Enhancer Browser.  
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4 CLASSIFICATION OF SOLID CANCER BY miRNAs EXPRESSION 
 
4.1 Material and Methods 
 
Microarray analysis was performed miRNA microarray assay on a CodeLink platform. 
The miRNA array consists of 4,104 probes printed in duplicate. This array can 
simultaneously profile more than 1,500 mature miRNAs and their corresponding 
precursor, all the other information were described in 3.1 material nad Methods 
section. We used our SQL miRNA internal database that contained the data retrieved 
from a large number of different experiments performed with miRNA microarray.  
       
 
4.1.1 Statistical Tests and Algorithms 
 
The Calculation of the Information Content was discussed in the section 3.1.2. 
Normalized, by using the quantiles method, microarray data were managed and 
analyzed by BRB-ArrayTools, version 3.8.1. Genes whose expression differed by at 
least 1.5-fold from the median, in at least 20% of the arrays were used. A stringent 
significance threshold was used to limit the number of false positive findings. The 
result of this approach was determined by 2 sample t test with nominal significance 
level at 0.001. The false discovery rate (FDR) is the expected proportion of positive 
results that are false positives at the various levels of significance and was controlled 
using the step-up method of Benjamini and Hochberg. In this analysis, at any 
selected FDR level, the expected proportion of false positives was determined. Class 
prediction algorithms determined whether miRNA expression patterns could 
accurately differentiate between the classes selected. We developed models based 
on the compound covariate predictor, nearest neighbor classification, and support 
vector machine. The models incorporated genes that were differentially expressed 
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among genes at the significance level (0.001) as assessed by the random variance t 
test. We used the prediction test to identify the classifier signature with the lowest 
misclassification error. We performed an unsupervised hierarchical clustering of the 
samples. The explanation of the decision tree and algorithm were described in 
section 3.1.3. Work flow of the experimental information that we have used for 
performing analysis using weka software are in APPENDIX B. 
 
4.2 miRNAs signatures in cancer samples 
 
In order to identify miRNA differentially expressed in several cancer, we investigated  
51 types of cancer in 3312 samples (2532 solid cancers and 780 leukemia samples). 
First, we compared all the solid cancer versus the normal tissues, this class 
comparison identified a list of miRNA differentially expressed in solid cancers (Table 
A6). MicroRNA described as oncogenes, for example: hsa-miR-21 and hsa-miR- 
17/20/25/92/103/106/146a were over-expressed, whereas microRNA characterized 
for a tumor-suppressor role, as miR-203/205 and miR-143/145, were down-
regulated. Second, we defined miRNA particularly expressed in some specific cancer 
calculating the information content. Hsa-miR-369-3pwas the most specific for the 
ovarian cancer, the second ( in order of IC value) was the hsa-miR-325, that it was 
expressed in  pancreas non-functioning endocrine cancer ( Figure 13 and Table A7).   
  
43 
 
 
 
Figure 13 miRNA specificity in tumors and leukemia (31 solid tumors and 20 leukemia 
types) sorted by Information Content (IC). 
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4.3 T-UCRs signatures in cancer samples 
 
We investigated the expression of T-UCR in several cancer samples in our database. 
After, a preliminary class comparison analysis between solid cancer versus normal 
counterparts we identified a list of T-UCR differentially expressed. Then, we 
calculated information content of every probes for the 27 cancer types (Figure 14). 
 
 
Figure 14 T-UCRs specificity in tumors and leukemia sorted by Information Content 
(IC). 
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 Uc.240 plus was the T-UCR presented  the highest value of IC, and it was 
expressed in chronic myelogenous leukemia and prostate adenocarcinoma.  The 
second, in order of IC value, was the uc.325 minus, and it was principally expressed 
in chronic myelogenous leukemia and hepatocellular carcinoma. This T-UCR is 
classified as intronic for the gene ELP4.  Uc.402 minus and uc.356 minus were both 
specific for chronic lymphocytic leukemia, uc.402 minus was located in an intronic 
region of the gene RPGRIP1L  and uc.356 minus was located in an intronic region of 
the gene MBNL2. 
 
4.4 Identification of putative “miRNA classifier”  
 
The first phase of this study consisted in the data collection process which involved 
the data cleaning and data preprocessing. Using our complex and large expression 
database, we tested the expression profile of microRNAs in a first cohort of 140 
training samples. 
 First, we random selected these 140 samples (training), that were represented by 
ten samples for fourteen several tumors. We inferred class prediction test  between a 
specific cancer versus the other type of cancer, to increase the specificity of our 
approach  we compared single solid tumor with other types of solid tumors (recursive 
feature elimination method was used to select 10 genes and Leave-one-out cross-
validation method was used to compute mis-classification rate, p-value < 0.001).  
These selection system was repeated for every class of cancer, identifying a list of 
miRNAs that were up- and down-regulated in these first cohort. These data from first 
array platforms identified a subset of 10 candidate microRNAs for any class of 
tumors: BLADDER CANCER, BREAST CANCER, COLON CARCINOMA, 
ESOPHAGUS CARCINOMA, GASTRIC CANCER, GLIOMA, HEPATOCELLULAR 
CARCINOMA, LUNG SQUAMOUS CELL CARCINOMA, MELANOMA, NSCLC 
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(NON-SMALL CELL LUNG CANCER), OVARIAN CARCINOMA,  PANCREAS 
CARCINOMA,  PROSTATE CARCINOMA. 
We repeated the same analysis, but this time we used other 140 randomized 
samples (test) selected in our database. Therefore, we obtaine  two different lists of 
significant miRNAs. After, we intersected the two lists: we finally selected 100 
microRNAs, listed in Table A8.  
The matrix of values of these 100 miRNAs that we have previously selected, was 
imported in weka software to infer an ultraselction system. First, for the all samples 
we have applied a supervised attribute filter. We used as evaluator: CfsSubsetEval 
and as searcher: BestFirst -D1 -N5.  Then. these processes have selected 31 
miRNAs, listed in Table A9 and after a final unsupervised attribute selection we had a 
list of 15 miRNAs, see table A10.  
To have a vision of the impact of expression of this 15 miRNAs in tumours, we 
performed two hierarchical clustered heatmaps. The expression profile of this group 
of miRNAs showed clearly pattern of differential up or down-regulated miRNAs. 
There were two heatmaps for the two cohorts of samples analyzed in the twenty solid 
cancers (Figure 15 and Figure 16). 
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Figure 15 Training test cohort of 15 miRNA 
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Figure 16 Test set cohort of 15 miRNA 
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4.5 Feature selection and classification  
 
The second part of this analysis was focused on the choice  of the classification for 
the solid cancer samples. We used two different algorithms: J48graft and JRip, two 
classifier able to investigate our dataset of solid cancer, that are respectively a 
decision-tree and a rule induction algorithm. First, we used the decision tree for our 
samples the J48graft algorithm (an implementation of  C4.5 classification algorithm), 
implemented in the weka software. The C4.5 classification algorithm is easy to 
understand as the derived rules have a very straightforward interpretation. In our 
study, we used all the selected attributes defined previously by supervised attribute 
filter. We used both the list of 31 miRNAs that the list of 15 miRNAs. We classified 
using the first 140 samples random selected as training set. All the output information 
are reported in Appendix B. After, we used the other cohort of 140 samples random 
selected for the test set. The decision tree developed describes 26 number of leaves. 
It was able to define the classes correctly with a weighted average of accuracy of  
79.3 %. We reported two considerations that appear in the testing set: the list of 15 
miRNAs’ list selected was more precise of the 2% than the 31 miRNAs’ list. When we 
analyzed all the leaves, we noted that the more difficulty was represented by the 
classification of esophagus cancer, that it was often confused with colon cancer. As 
reported in the confusion matrix below. 
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  a   b  c  d   e  f  g  h  i    j   k  l  m  n   <-- classified as 
 18  0  0  0  0  0  0  0  1  1  0  0  0  0 |  a = BLADDER CANCER 
  2 15  2  0  0  0  0  0  0  0  1  0  0  0 |  b = BREAST CARCINOMA 
  0  1 17  1  0  0  0  0  0  0  1  0  0  0 |  c = COLON CARCINOMA 
  0  0  5 12  0  0  0  0  1  0  2  0  0  0 |  d = ESOPHAGUS CARCINOMA 
  0  0  0  1 17  0  1  1  0  0  0  0  0  0 |  e = GASTRIC CANCER 
  0  1  0  0  0  9  0  0  0  0  6  0  0  4 |  f = GLIOMA 
  0  0  0  0  0  1 18  0  0  0  0  0  1  0 |  g = HEPATOCELLULAR CARCINOMA 
  0  0  0  0  0  1  0 18  0  0  0  0  1  0 |  h = KIDNEY CARCINOMA 
  4  0  1  0  0  1  0  0 13  0  1  0  0  0 |  i = LUNG SQUAMOUS CELL CANCER 
  1  0  0  0  0  0  0  0  0 18  1  0  0  0 |  j = MELANOMA 
  0  0  0  0  0  0  0  0  0  0 20  0  0  0 |  k = NSCLC 
  0  0  0  0  0  0  0  3  0  0  4 11  2  0 |  l = OVARIAN CARCINOMA 
  0  0  0  0  0  0  0  1  0  0  0  0 19  0 |  m = PANCREAS CARCINOMA 
  1  0  0  0  0  1  0  0  0  0  0  0  1 17 |  n = PROSTATE CARCINOMA 
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We used JRip following the same data and passage:  it generated the rules for the 
classification, that we reported below.  
 
 
 
 
 
(hsa-miR-383 <= 4.417) and (hsa-miR-30c-1* >= 4.024) and (hsa-miR-215 <= 5.322) => 
Class=LUNG SQUAMOUS CELL CARCINOMA (11.0/3.0) 
(hsa-miR-9 >= 8.487) => Class=GLIOMA (10.0/2.0) 
(hsa-miR-122 >= 11.89) => Class=HEPATOCELLULAR CARCINOMA (9.0/0.0) 
(hsa-miR-145 <= 3.852) and (hsa-let-7e >= 9.894) => Class=PROSTATE CARCINOMA (9.0/0.0) 
(hsa-miR-383 >= 9.519) => Class=MELANOMA (9.0/1.0) 
(hsa-miR-15b >= 8.367) and (hsa-miR-218 <= 4.893) => Class=BREAST CARCINOMA (8.0/1.0) 
(hsa-miR-145 >= 11.285) and (hsa-miR-383 >= 6.18) => Class=GASTRIC CANCER (8.0/0.0) 
(hsa-miR-145 <= 7.731) and (hsa-miR-193b <= 8.717) => Class=NSCLC (9.0/1.0) 
(hsa-miR-330-5p >= 8.863) => Class=NSCLC (2.0/0.0) 
(hsa-miR-330-5p >= 7.761) and (hsa-miR-122 <= 7.731) => Class=BLADDER CANCER (4.0/0.0) 
(hsa-miR-218 <= 3.513) and (hsa-miR-10a <= 9.198) => Class=BLADDER CANCER (4.0/0.0) 
(hsa-miR-145 <= 9.173) and (hsa-miR-375 <= 8.103) => Class=OVARIAN CARCINOMA (8.0/1.0) 
(hsa-miR-330-5p <= 3.533) => Class=KIDNEY CARCINOMA (5.0/0.0) 
(hsa-miR-218 >= 7.41) => Class=PANCREAS CARCINOMA (12.0/2.0) 
(hsa-miR-383 >= 7.298) => Class=ESOPHAGUS CARCINOMA (11.0/3.0) 
 => Class=COLON CARCINOMA (21.0/12.0)  
 
 
 
Observing the rules we noted that for a classification of cancers sample, these 
system utilized only a single miRNA value. For example, hsa-miR-9 is sufficient to 
discriminate the Glioma class; this finding was well characterized in literature. In fact, 
recently miR-9, basing on data from the Tissue Cancer Genome Atlas (TCGA 
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https://tcga-data.nci.nih.gov/tcga/), was specific to a particular subtype of glioma, 
characterized by oligoneural precursor [93]. Similarly, the hsa-miR-122 was specific 
for the Hepatocellular carcinoma with a high value of expression [68, 94] .  
We noted that the accuracy for a corrected classification of the classes was 68.2%. 
Therefore the J48 system have a better classification accuracy. These type of 
classification, used an interpretation based on combinations of one-to three 
microRNAs in each node to make a decision, it  will be useful for the identification of 
the tissue origin of  cancers of unknown primary origin (CUP), a significant fraction of 
cancers that presented one or more metastases but where it was not possible 
identify the tissue of origin. Other previous study have been shown models based on 
miRNAs expression for the identification of tumor tissue origin of CUP [95, 96].   
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5 REPROGRAMMING OF miRNA NETWORK  
 
5.1 Material and Methods  
  
We used several bionformatic tools that we described in the sections above. An SQL 
miRNA internal database was built with the data retrieved from a large number of 
different experiments performed in our laboratory.        
 
5.1.1 Data analysis  
 
The union of the target mRNAs was used as an input to DAVID EASE, using the 
David Bioinformatics Resources system (http://david.abcc.ncifcrf.gov). We compared 
the list of terms related to the predicted targeted mRNAs. 
The terms were evaluated by p value (P < 0.05) and Benjamini– Hochberg correction 
for multiple testing controlled the P values. Target genes selection was carried out by 
Diana microT.  
 
5.1.2 Network generation  
      
We used Banjo to infer the Bayesian network for the different tissues and diseases. 
Banjo is a software application and framework for structure learning of static and 
dynamic Bayesian networks and it was designed from the ground up to provide 
efficient structure inference when analyzing large, research-oriented data sets. Banjo 
focuses on score-based structure inference. Banjo have as core of the algorithm a 
“searcher”.  
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The first step, Proposer, consists in selecting a graph structure, Grough, to be 
evaluated according to the data. The strategies currently implemented in Banjo are 
the simulated annealing and the hill climbing. The graph Grough is then scanned for 
cycles, Cycle Checker, and the acyclic graph G generated. The two possible 
strategies to visit the graph and remove the cycles are the Breadth First Search e 
Depth First Search. The acyclic graph G is then evaluated, Evaluator, according to a 
scoring function. Banjo implements a Bayesian score, dened as the logarithm of the 
probability of the proposed graph model given the data. The Decider decides, 
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possibly stochastically, whether to accept the proposed network (as the new current 
network) and best scored networks are then reported. For each tissue or disease all 
the mature expressed and varying miRNAs were used as input to Banjo.  
The expression values were preprocessed with Gene Pattern to only filter out non 
varying miRNAs, according to the following parameters: #filter.flag = filter (Variation 
filter and thresholding flag); #preprocessing.flag = no disc or norm (Discretization and 
normalization flag); #minchange = 10 (Minimum fold change for filter); #mindelta = 
512 (Minimum delta for filter); #threshold = 64 (Value for threshold); #ceiling = 20000 
(Value for ceiling);#max.sigma.binning = 1 (Maximum sigma for binning);#prob.thres 
= 1 (Value for uniform probability threshold filter); #num.excl = 2% of total chips 
(Number of experiments to exclude (max & min) before applying variation filter); 
#log.base.two = no (Whether to take the log base two after thresholding); 
#number.of.columns.above.threshold = 17 1% of total chips (Remove row if n 
columns not >= than given threshold above.threshold); #column.threshold = 512 
(Threshold for removing rows). We then performed a quality control step to remove 
chips with abnormal expression distribution across miRNAs: chips were retained only 
if less than 25% of miRNAs were absent (expression value <64). Similarly, miRNAs 
were retained only when less than 25% of samples had absent expression (value 
<64). The static Bayesian network inference algorithm was run on the miRNA 
expression matrix by using standard parameters, with a discretization policy of q6. 
Consensus graphs, based on top 100 networks, were obtained from at least 8 x109 
searched networks. We applied the MCL graph-based clustering algorithm to 
extraction of clusters (i.e. groups of densely connected nodes) from miRNA 
networks. We used MCL (Neat), an unsupervised cluster algorithm for graphs based 
on simulation of (stochastic) flow in graphs, that has been shown to enable good 
performances in extracting co-regulated genes from transcriptome networks.  
We used yEd graph editor (yFiles software, Tubingen, Germany) for graphs 
visualization. 
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5.2 miRNA Bayesian network of normal samples  
 
We applied Banjo to infer the Bayesian network for normal tissues. miRNA relations 
were modeled as graphs where nodes represent the miRNAs and colored edges the 
relationships between them. We extracted coherent groups of nodes by adopting 
clustering algorithms, in order to discover miRNA groups with highly related 
expression patterns. We used the MCL graph-based algorithm (Enright et al. 2002). 
Figure 17 displays the miRNA network of normal tissues, obtained from over 1000 
samples and 50 cell types/tissues. We used all of the expressed miRNAs to build the 
Bayesian networks (rather than only the differentially expressed ones). The MCL 
clusters with high co-expression patterns throughout normal tissues are linked by 
specific colored edges.  
 
Figure 17 miRNA network in normal tissues (1107 samples, 50 tissues, 115 miRNAs) 
 
57 
 
We find in literature some confirmations about our network developed. The 
proliferation cluster hsa-miR-106a/b/93 linked to hsa-miR-20a/17 and to hsa-miR-
25/92a (MYC associated) includes hsa-miR-223 is involved in cell cycle progression 
[97]. In the opposite side, on the left of the image, we find hsa-miR-133a/b were in a 
cluster with hsa-miR-1 (light orange) and all were involved in skeletal muscle 
proliferation and differentiation. A close cluster is hsa-miR-10a/b and hsa-miR-214 
(green). hsa-miR-214 can modulate the expression of genes regulated by Hedgehog. 
Inhibition of hsa-miR-214 resulted in a reduction or loss of slow-muscle cell types, so 
these muscle/differentiation clusters are linked to hsa-miR-143/145 [98]. The hsa-
miR-145 node links the proliferation clusters described above to the muscle 
differentiation clusters.  
The hsa-miR-29 family, targets genes are induced in quiescence [99], is linked to 
hsa-miR-30 and to hsa-miR-15/16, miRNAs that target the anti-apoptotic protein 
BCL2.  Hsa-miR-221-222, are considered regulators of the cell cycle, together with 
hsa-miR-206, hsa-miR-155 (pre-B cell proliferation), and hsa-miR-130a/b are in a 
yellow cluster [74].  
In one of the center branch the hsa-miR-200 family, hsa-miR-203 and hsa-miR-205 
are known to be directly involved in TGF-β mediated EMT and differentiation [100]. 
hsa-miR-181 family members are involved in hematopoietic differentiation [101].  
Has-miR-145 act as an hub for hsa-miR-181, hsa-miR-200, hsa-miR-205, hsa-miR-
215, so the loss of the hsa-miR-145 might also impact the TP53/EMT/differentiation 
branch. Another important hub appears to be hsa-miR-16, which is located in the 
other half of the net and coordinates hsa-miR-29 and hsa-miR-221/206/155/130 
clusters. Together, miR-15 and miR-16 function by targeting multiple oncogenes, 
including BCL2, MCL1, CCND1, and WNT3A [102]. The hsa-miR-16 hub also feeds 
the hsa-miR-26/let-7/hsa-miR-302 branch. hsa-miR-26 and their host genes 
cooperate to inhibit the G1/S transition by activating the pRb protein [103]. Let-7 
regulates Ras and hsa-miR-302 are expressed in ES cells and other early embryonic 
tissues.  
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5.3 miRNA Bayesian network of solid cancers  
 
Initially, we started inferring a global miRNA expression network for solid cancers 
(Figure 18). The most connected hub was represented by hsa-miR-30c (degree 10), 
followed by hsa-miR-16 (degree 6). In the normal condition, hsa-miR-16 was the 
most connected node (degree 8) and hsa-miR-30c had only a low degree of 3. In the 
opposite way we identified: hsa-miR-215 (degree 6 in normal tissues and 3 in 
cancer) and hsa-miR-103/106a (degree 5 in normal tissues and only 1 in cancer). 
The exchanges of hubs between non-malignant and cancer tissues was the first 
notable sign of divergences in their respective miRNA programs. The MCL clustering 
algorithm was employed to map the sub-networks with high co-expression patterns 
(these MCL clusters, or cliques, are linked by specific colored edges). For simplify 
the visualization of the miRNA according to their differential expression in tumors, we 
color-coded the miRNA nodes (red = over-expressed; green = down-regulated). 
Neighbors preferentially appeared with the same trend, reflecting clustered miRNAs 
were either over-expressed or down-regulated. For example, hsa-miR-17/20a, hsa-
miR-106a/b, and hsa-miR-93 were all up-regulated in cancers.  
Conversely, hsa-miR-143/145, hsa-miR-133a/b, hsa-miR-214 and hsa-miR-138, all in 
the same co-expression clique, were down-regulated.  
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Figure 18 The miRNA network in solid cancers (2532 samples, 31 cancer types, 120 
miRNAs). The network was inferred for all expressed and varying miRNAs, without 
preselecting for differential expression. miRNAs are either red (over-expressed) or 
green (down-regulated).  
 
The single graph in the overall solid cancer net can be explained only by the same 
miRNAs having variable roles in a range of cancers, as in normal condition it can 
regulated different expressed targets in a specific tissues. Afterwards, we focused on 
the investigation of selected cancer types (lung, colon, breast, prostate). For each 
cancer tissues we built graphs for normal and cancer tissues and applied MCL to 
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extract miRNA co-expression clusters. Lung cancer the first that we analyzed; the 
adenocarcinomas’ miRNome was represented by 1 major and 8 unconnected sub-
networks, while the normal counterpart was a single complete miRNA network Figure 
19).  
 
Figure 19 Comparison of miRNA networks in normal lung and adenocarcinoma. A) 
Normal lung (71 samples). The figure shows a single complete miRNA network. B) 
Lung adenocarcinoma (125 samples). 
Notably, for the other cancer investigated: colon, breast, and prostate cancers 
(Figure 20,21 and 22 respectively) the disjoint trends appear similar to lung cancer, 
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consequently we have many disjoint miRNA network. In order to understand if this 
miRNA nets were involved in a similar pathway and which role that can exhibit in 
cancer, basically we compare the disjoint nets’ tumors and we identified a number of 
notable, and often common, miRNAs in the unconnected clusters. 
 
 
 
Figure 20 MicroRNA genetic network in colon adenocarcinoma 
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Figure 21 MicroRNA genetic network in breast cancer 
 
 
Figure 22 MicroRNA genetic network in prostate cancer 
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The microRNA found in common with the cancer were: 
- hsa-miR-10a/b : identified in lung, colon and breast cancers; 
- hsa-miR-26a/b: identified in colon and prostate cancers; 
- hsa-miR-29a/b: identified in breast, colon, and lung cancers; 
- hsa-miR-181 family members: identified  in  breast, colon and prostate 
cancers. 
The hsa-miR-10a/b and hsa-miR-26a/b were well known key miRNAs implicated in 
several solid cancer  [104]. Hsa-miR-29a/b and hsa-miR-181 were two most studied 
over-expressed miRNAs  in multiple cancers and their role was associated with 
tumorigenesis and cancer progression [105]. At last, these two miRNAs’ family were 
implicated in leukemia too,  thus we can suppose a coordinated roles depending on 
the context and that can miRNAs can act as either oncogenes or tumours 
suppressors. Other miRNA cliques included hsa-miR-200c [106], linked to TP53-
associated hsa-miR-192/215 in a colon sub-network, and high levels of miR-215 
conferred chemoresistance due to cell cycle arrest and reduced cell proliferation in 
colon cancer patients [107]. Finally, we concluded that miRNA networks were 
reprogrammed in solid cancer and the expression of few notable miRNAs was 
independent from the major network. 
   
5.4 miRNA Bayesian network of leukemia   
 
We generated the networks for two hematological cancers, acute myeloid leukemia 
(AML) and chronic lymphocytic leukemia (CLL). MiRNA profiling of these two 
hematological malignancies have been well investigated and many data have 
generated a miRNA signatures about diagnosis, cytogenetics and prognosis [108]. 
The miRNA network in AML also had disjointed cliques (Figure 23). The most 
prominent finding here was that hsa-miR-155 and hsa-miR-181, two miRNAs with 
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clinical relevance were positioned in two separated sub-networks. In fact hsa-miR-
155 was miR-155 has been shown to promote myeloid development and function 
and play a positive role in the promotion of cancer and autoimmunity [109], while the 
increment of the expression levels of hsa-miR-181 family members have been shown 
to be associated with favorable outcome in patients with cytogenetically normal acute 
myeloid leukemia , in opposite the   up-regulation of a HOXA-PBX3 homeobox-gene 
signature following down-regulation of hsa-miR-181 is associated with adverse 
prognosis in patients with cytogenetically abnormal AML  [110]. In fact, hsa-miR-181 
was associated to hsa-miR-146a in a detached yellow mini-clique [111]. Has-miR-
155 was in the same green clique of hsa-miR-223, hsa-miR-92a, hsa-miR-25 and 
hsa-miR-32. Finally, hsa-miR-29b has a key role in AML and, in accordance, it acts 
as a hub in the AML net [112].  
 
Figure 23 The miRNA network in acute myeloid leukemia (589 samples) 
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In chronic lymphocytic leukemia (CLL) two small cliques were separated from the 
main net (Figure 24): hsa-miR-23a/b [113] and the second one embracing the hsa-
miR-15a and has-miR-195 and has-miR-16. miR-15/16 were miRNAs frequently 
deleted in CLL, functioned by targeting multiple oncogenes, including BCL2, MCL1, 
CCND1, and WNT3A [102]. Thus, the network topologies for these two leukemias 
could recapitulate their respective molecular pathology, with the key hsa-miR-29b 
acting as a hub in AML, but it was presented only in a branch in CLL. AML prognostic 
hsa-miR-181 was disjointed in AML but not in CLL, with the reverse being true for the 
CLL prognostic hsa-miR-15/16 pair. 
 
 
Figure 24 The miRNA network in chronic lymphocytic leukemia (254 samples) 
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6 IN SILICO, IN-VITRO AND IN-VIVO VALIDATION  
 
6.1 Material and Methods 
 
The in vitro analyses were performed in cell line. For in silico validation we used 
several bionformatic tools. We used array comparative genomic hybridization 
(aCGH) using samples from selected GEOdatasets and Stanford Microarray 
Database (SMD) resumed in Table A11. 744 arrays were studied (537 samples from 
GEO and 207 from SMD). All platforms were 2-channel based, data were 
downloaded as normalized values, and genes were annotated according to the gene 
symbol. All normalized log ratios were converted to log2 ratios. Bootstrap analysis 
was used (10,000 random swaps of cancer and control channels) to obtain p-values 
and confidence limits for deletion and amplifications. We investigated 306 miRNA 
loci; 168 miRNA loci were associated to a host gene, and 138 miRNA loci to the 
flanking genes. miRNA families were defined according to TargetScan. The threshold 
p-value for a miRNA family was set at 0.05 to the number of family members. To 
control for multiple testing, we performed 100 bootstrapping cycles and used the 
results to calculate the FDR.  
We used for target genes selection a software (described in introduction) DIANA-
miRpath. After, the union of the target mRNAs with a score above 3 was used as an 
input to ClueGO [114]. ClueGO visualizes the selected terms in a functionally 
grouped annotation network that reflects the relationships between the terms based 
on the similarity of their associated genes. ClueGO was used to relate differential 
expression in cancer to functional pathways (KEGG). The size of the nodes reflects 
the statistical significance of the terms. The degree of connectivity between terms 
(edges) is calculated using kappa statistics. The calculated kappa score is also used 
for defining functional groups. A term can be included in several groups. The re-
occurrence of the term is shown by adding ” n”. The not grouped terms are shown in 
white color. The group leading term is the most significant term of the group. The 
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network integrates only the positive kappa score term associations and is 
automatically laid out using Organic layout algorithm supported by Cytoscape. Right-
sided hyper-geometric test yielded the enrichment for GO-terms. Benjamini-
Hochberg correction for multiple testing controlled the p-values. 
 
      
6.1.1 Cell line culture 
 
Embryonic stem (ES) cell lines were cultured at 37°C and 5% CO2 in specific 
medium. Total RNA was extracted by using TRIZOL method. To remove of 
contaminating genomic DNA from RNA samples, 1 µg each of them are treated with 
1U DNase I Ampl Grade (Invitrogen) in final reaction volume of 10 µl. The incubation 
time was 10 minutes at room temperature. The enzyme was inactivated by addition 
of 25mM of EDTA solution followed by heating at 65°C for 10 min. 
 
6.1.2 Isolation and reverse transcription of a total RNA 
 
We collected tissue samples from mice. Sections from each tissue sample were 
lysed in TRIZOL reagent (Invitrogen Life Techonolgies, Carlsbad, CA USA). Total 
RNA was extracted using a standard protocol followed by purification with the Qiagen 
RNeasy Mini Kit (QIAGEN Inc, Valencia, CA USA). RNA purity was assessed by the 
ratio of spectrophotometric absorbance at 260 and 280 nm (A260/280nm) using 
NanoDrop ND-1000 (NanoDrop Inc, Wilmington, DE USA). 
Total cellular RNA (800 ng) was reverse transcribed using random hexamers 
(20pmoles Invitrogen Life Technologies, Carlsbad, CA ) and 1mM dNTP mix in a total 
reaction volume of 10 µl. The mixture was incubated at 65°C for 5 minutes for 
denaturization, and snaped cooled. SuperScript III enzyme (200 U ,Invitrogen) was 
added to the mixture, with 100 mM MgCl2, 0.2 M DDT and 40 U of RNase OUT 
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(Invitrogen Life Technologies) in final reaction volume of 20 µl. The reaction was 
incubate at 25°C for 10 minutes followed by 50 minutes at 50°C, followed by 85°C for 
5 minutes and chilled in ice. To increase the sensitivity of the PCR reaction we added 
2 U of RNase H to remove the RNA template from cDNA:RNA hybrid molecule. 
Finally, the resulting cDNA was diluited to a final concentration of 10 ng/ul.  
 
6.1.2 Real-time PCR 
 
In order to quantify T-UCRs we used realt-time PCR, with SYBR green chemistry. 
The qPCR reaction was carried out in a total volume of 10 µ,l containing 10 ng of 
cDNA, 2X SYBR Green Mastermix ( BioRAD) and 100nM of the specific UCR primer 
mix. The 18S rRNA was used as reference gene. Reactions were setup in 384-well 
plates. All reactions were performed in triplicate. Cycling conditions were as follows: 
95°C for 3 minutes, 40 cycles at 95°C for 15 seconds and at 60°C for 1 minutes, 
followed by a melting curve. For each cDNA template, the triplicate T-UCR Ct values 
were averaged, and the normalized Ct (∆Ct) was calculated by subtracting the mean 
Ct value for 18S rRNA from each T-UCR mean Ct value. 
        
 
6.2 Real-Time PCR confirms the uc.283 plus specificity for ESC 
 
To validate our microarray data that have showed uc.283 plus specific for embryo 
statement, we used quantitative real time polymerase chain reaction (RT-qPCR) on 
RNAs extracted from ESCs and five mouse adult tissues (spleen, seminal vesicles, 
thymus, lung, and bone marrow). We used miR-302 as a positive control, a miRNA 
specifically expressed in ESCs, as we have shown previously. The RT-qPCR (Figure 
25) confirmed strong and ESC-specific expression for both miR-302 and uc.283 plus 
(Wilcoxon test p-value <0.01).  
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Figure 25 Real time PCR confirms the results of the microarray analysis. The uc.283 
plus is expressed at higher levels in the embryonic stem cells (ES) than in the adult 
tissues, such as spleen, seminal vesicles (SV) , thymus, lungs and bone marrow (BM). 
The miR-302 was used as a positive control. Graph include labeled error bars and ** 
represents the p-value < 0.01 
 
  Expression data values were listed in Table A12. No reported enhancer activity was 
associated using the Vista Enhancer Browser with uc.283 at E11.5. In a further 
quest to investigate uc.283 function, we studied a 2,000 bp region surrounding this 
UCR on the UCSC Genome Browser (Figure 26). In the H1-hESC Chromatin State 
Segmentation (HMM track from ENCODE/Broad), this sequence might be an 
inactive or poised promoter. Moreover the uc.283 locus presented a low signal for 
H3K4me1 in the histone modification ChIP-Seq data of the H1 ESC line, suggesting 
possible monomethylation. Monomethylation at H3K4me1 is a marker for the 
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presence of an active enhancer, in contrast to promoters, marked by trimethylation 
of histone H3 at lysine residue 4 (H3K4me3).  
In addition, the edges of uc.283 overlap the initial tracts of two open chromatin 
regions (OpenChrom_15681 and OpenChrom_15682). Data from the methyl 450K 
bead array track (ENCODE/HAIB) showed that, in close proximity to the start of uc. 
283 plus, the CpG sequence was unmethylated in H1-hESC and Human Umbilical 
Vein Endothelial Cells (HUVECs), and partially or totally methylated in other cell 
types. These findings, together with the proximity to open chromatin regions, 
strengthen the possibility that during embryonic development and in ESCs uc.283 
plus could be located in a euchromatinic region and be transcribed.  
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Figure 26 Analysis of uc.283 plus using UCSC genome browser. 
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6.3 Functional genome analysis: in silico validation 
 
Functional annotation analysis investigated the involvement of non-coding RNA in 
several cellular processes. There are two way to understand and evaluate the 
previously insights. First, it is necessary explicated which are the target genes of the 
specific miRNAs differentially expressed, over and under-regulated in cancer 
samples. Second, it is possible used the target genes of the miRNAs (reverse 
expression analysis) that characterized the disjoint network previously analyzed in 
the section 5. Consequently, we used DIANA-miRpath in order to find target mRNAs. 
After, the union of the target mRNAs with a score above 3 was used as an input to 
DAVID EASE and ClueGO to investigate the pathway. Finally, we obtained a KEGG 
pie-chart corresponding to the functional effect of differentially-expressed miRNAs on 
cellular pathways, simultaneously targeted by both up-regulated and down-regulated 
miRNAs (Figure 27). Most of the affected pathways are related to cancer or signal 
transduction (i.e. Wnt, VEGF, TGF-beta, insulin, and phosphatidylinositol signaling, 
focal adhesion and colorectal cancer).  
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Figure 27 The KEGG pie-chart shows the functional effect of differentially-expressed 
miRNAs on cellular pathways in cancer. 
 
 
For lung cancer we had identified 8 minor sub-networks unconnected in cancer, so 
we inferred a KEGG functional analysis of the miRNAs in the 8 minor sub-networks 
unconnected. The results showed that the miRNA which are present in the un-
connected cliques target genes which are involved in many cancer-related terms, 
such as focal adhesion, small cell lung cancer, calcium signaling. (Figure 28).  
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Figure 28 The KEGG functional analysis of 8 disjointed minor miRNA networks in lung 
adenocarcinoma. 
 
Additionally, we used data from array comparative genomic hybridization (aCGH) to 
verify where the over or under-expression of miRNA differentially expressed in 
cancer is connected to genomic region amplified o deleted. We calculated, for each 
of 20,000 different chromosomal locations, two p-values, one for deletion and one for 
amplification. To measure miRNA copy number alterations we used their respective 
host genes or, when unavailable, their two flanking genes. In the Figure 18 we 
showed amplified and deleted miRNA families. The results from aCGH were overlaid 
on the expression network in solid cancers. The node labels, for which expression 
and physical alteration were concordant (i.e. over-expression and amplification), 
were embolden and visually reinforced with a hexagonally shaped border.   The 
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detection of amplified hsa-miR-17-5p/20/93/106 family using flanking genes was a 
successful validation of our approach. Genomic amplification and elevated 
expression of mir-17-92 were both found in several human B-cell lymphomas, and its 
enforced expression exhibits strong tumorigenic activity in multiple mouse tumor 
models. In the Figure 18 the hsa-mir-17-92 cluster was in the midst of the cancer 
network. The top deleted miRNA family was hsa-miR-204/211, followed by other 
families including hsa-miR-200b/c/429, hsa-miR-141/200a, hsa-miR-125/351, and 
hsa-miR-218. 
  
6.4 In vivo validation 
 
Finally, we experimentally validated the miRNA network with acute lymphocytic 
leukemia originated in Mir155 transgenic mice.  We compared the miRNA profiles of 
three leukemia samples from these Mir155 transgenes to controls from wild type 
mice (Table A. Then we located the positions in the network for the miRNAs 
regulated in the transgene’s leukemias, most of miRNAs deregulated in these 
transgenic mice were located close to hsa-miR-155 in the cancer network. The yellow 
nodes appeared concentrated around the hsa-miR-155 node (black). We separated 
with a diagonal  the hsa-miR-155 half from the other one and we compared the two 
sides: the difference in yellow nodes concentrations was significant (14 vs. 43 , 4 vs. 
57, Fisher exact test, 2-tail p-value<0.009). Interestingly the topological distribution of 
hsa-miR-29s and hsa-miR-181s were not considered as hsa-miR-155 regulated. In 
fact, hsa-miR-181 over-expression and hsa-miR-29 down-regulation are hallmarks 
miRNAs in leukemia, and this finding confirmed the independency of these events in 
cellular transformation.  
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Figure 29 Deregulated miRNAs in leukemia from miR-155 transgenic mice are 
preferentially located close to miR-155 in the cancer network. 
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7 FINAL DISCUSSION 
 
Non-coding RNAs were considered the most important novel arms of human post-
transcriptional regulatory tools. They can specifically target different genes, often in a 
one-to-many way. Therefore fine-tuning the level of a single non-coding RNA might 
affect many pathways in a pleiotropic mode. In fact the effects of microRNAs on cell 
pathology and physiology are likely to be complex, each miRNA can control 
translation of tens or even hundreds of different coding messengers and a single 
mRNA can be controlled by more than one microRNA. 
 Thus, we have proposed a study of non-coding RNAs in cancer by applying a 
systems biology approach.  
First, we presented a thorough analysis of miRNAs tissue specificity in 50 different 
normal tissues grouped by 17 systems, corresponding to 1070 human samples. We 
have found that a small set of miRNAs were tissue-specific while many others were 
broadly expressed. In the same way, we tested the expression of T-UCRs in 374 
normal samples from 46 different tissues, grouped by 16 systems. We studied the 
global changes of T-UCRs expression, and only few T-UCRs were tissue-specific. 
We focused our study on the unique T-UCR specific for the embryonic condition, 
uc.283plus. We confirmed this specificity by Real-time PCR and we proposed this 
conserved transcript as a potential novel molecular marker of stemness. Furthermore 
we considered as a possible future investigation the uc.283 plus expression in cancer 
stem cells sub-populations. 
We also investigated oncologic or hemato-oncologic disorders and identified cancer 
type-specific miRNAs and T-UCRs. Then, we used the differential expressed 
miRNAs to classify solid cancers. We tested and compared  two different 
approaches: J48graft and JRip, that respectively were a decision-tree and a rule 
induction algorithm. By the computational optimization of these  two classifiers we 
can correctly defined the type of solid cancer. We suggested, on the basis of the 
results, that a further implementation can be useful to increase the percentage of 
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corrected classification, in order to apply this tool for the investigation of cancer of 
unknown primary origin. 
Afterwards, we inferred genetic networks directly from miRNA expression data for 
normal tissues and for several solid tumors and leukemia. We found that the normal 
tissues were represented by single complete miRNA networks, while the cancers 
were characterized by separate and unlinked miRNA sub-networks.  
In fact, we analyzed in depth the sub-networks of the cancers and we found miRNAs 
independent from the general transcriptional program involved in specific cancer-
related pathways. We confirmed our finding by several functional genome validation 
methods. 
We investigated also two hematological malignancies: acute myeloid leukemia and 
chronic lymphocytic leukemia. MiRNAs related to AML and CLL pathogenesis 
presented a different behavior respect solid cancers and there were only one and two 
sub-networks respectively. The different observance of solid cancers and leukemia 
might be due to the diverging pathogenesis mechanisms that include differing 
oncogenic miRNA networks.  
Finally, all these finding, taken together, leads us to conclude that the bioinformatics 
tools and analysis of “big data” with a system biology approach were fundamentals to 
try to understand the complexity of the biology of the cancer.  
We have analyzed only a part of a huge human genomic landscape, two classes of 
the non-coding RNA side. Our findings permit us to have contributed to a better 
analysis of the functions of miRNAs and T-UCRs and their global impact that can 
effect on the pathogenesis of cancer.   
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APPENDIX  A 
Table A1 Relevant miRNAs associated to solid cancers. 
 
 
Table A2 Prominent miRNAs associated to Luekemia. 
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Table A3 . Expression levels of tissue specific microRNAs in normal tissues. 
Sorted by information content (IC).  
Name Tissue Specificty 
Expression  
Value 
Information  
Content 
Chromosomal Location 
miR-302a EMBRYO 4380 4.00 4:113569339-113569407  
miR-302c EMBRYO 1709 3.99 4: 113569519-113569586  
miR-302b EMBRYO 4929 3.73 4: 113569641-113569713  
miR-338-5p 
EPIDERMIS / 
NERVOUS SYSTEM 
573 / 451 2.51 17: 79099683-79099749 
miR-323-3p NERVOUS SYSTEM 167 2.47 14: 101492069-101492154  
miR-335 BREAST 322 2.37 7: 130135952-130136045  
miR-124 NERVOUS SYSTEM 533 2.33 
8:9,798,308-9,798,392 
8:65,454,260-65,454,368 
miR-139-5p NERVOUS SYSTEM 245 2.27 11: 72326107-72326174  
miR-371-5p EMBRYO 443 1.93 19: 54290929-54290995 
miR-325 EPIDERMIS 129 1.91 X: 76225829-76225926  
miR-133a 
CARDIOVASCULAR 
SYSTEM / SKELETAL 
MUSCLE 
464/ 661 1.88 
18:17,659,657-17,659,744 
20:60,572,564-60,572,665 
miR-184 
RESPIRATORY 
SYSTEM 
259 1.86 15: 79502130-79502213  
miR-133b 
CARDIOVASCULAR 
SYSTEM / SKELETAL 
MUSCLE 
394 / 371 1.83 6: 52013721-52013839 
miR-211 NERVOUS SYSTEM 180 1.78 15: 31357235-31357344 
miR-9 NERVOUS SYSTEM 1346 1.73 
1:154656757-154656845 
5:87998427-87998513 
miR-370 NERVOUS SYSTEM 146 1.72 14: 101377476-101377550  
miR-376c EPIDERMIS 121 1.61 14: 101506027-101506092  
miR-132 NERVOUS SYSTEM 552 1.59 17: 1953202-1953302  
miR-1 
SKELETAL MUSCLE / 
CARDIOVASCULAR 
SYSTEM 
500 / 350 1.56 
20:60,561,958-60,562,028 
18:17,662,963-17,663,047 
miR-215 KIDNEY 2630 1.55 1: 220291195-220291304 
miR-339-5p LIVER 107 1.54 7: 1062569-1062662  
miR-330-3p LIVER 125 1.53 19: 46142252-46142345  
miR-342-5p EPIDERMIS 326 1.49 14: 100575992-100576090  
miR-199b-5p 
RESPIRATORY 
SYSTEM 
144 1.39 9: 131007000-131007109  
miR-129-3p NERVOUS SYSTEM 266 1.36 11: 43602944-43603033  
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Table A4 Expression levels of tissue specific microRNAs during differentiation 
of embryonic stem cells (ES) . Sorted by information content (IC).  
 
Name Embryonic tissue Specificity 
Expression  
Value 
IC 
miR-211 EB 14 day 165 2.65 
miR-10b Monolayer 909 2.20 
miR-138 EB 7 day 181 1.88 
miR-218 Monolayer 665 1.65 
miR-122 Monolayer 3660 1.57 
miR-99a Trophoblast 197 1.54 
miR-215 Monolayer /Definitive Endoderm 1673 / 325 1.42 
miR-338-3p EB 7 day 432 1.26 
let-7e iPS / Embryonic Stem Cells 284 / 181 1.23 
miR-371-5p EB 14 day / EB 7 day / ES 
1424 / 6274 / 
848 1.20 
miR-148a Monolayer 158 1.18 
miR-181c Trophoblast / Monolayer 1500 / 927 1.07 
miR-203 
EB 14 day / Monolayer / 
Trophoblast 974 / 750 / 934 1.05 
miR-181a Trophoblast / Monolayer 2943 / 1106 0.99 
miR-181b Trophoblast / Monolayer 8290 / 3397 0.93 
miR-192 Monolayer / Definitive Endoderm 1804 /474 0.84 
miR-150 EB 7 day / iPS 501 / 347 0.83 
miR-139-3p iPS / ES 477 / 250 0.82 
miR-27b Trophoblast / Monolayer 554 / 317 0.77 
miR-10a Monolayer 2547 0.75 
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Table A5 T-UCRs bidirectional in normal cluster tissues.  
 
Chromosoma  Quantity of T-UCRs T-UCRs bidirectional 
1 22 5 
2 21 6 
3 9 2 
4 7 2 
5 21 5 
6 6 1 
7 13 3 
8 5 1 
9 17 2 
10 22 8 
11 10 3 
12 8 3 
13 7 1 
14 10 1 
15 5 1 
16 4 1 
17 5 2 
18 3 0 
19 8 4 
20 2 1 
22 1 0 
X 18 5 
TOT 224 57 
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Table A6 Up-regulated and Down-regulated microRNAs in 31 types of solid cancers 
(2532 cancers samples vs. 806 corresponding normal samples).  
Parametric 
p-value  
FDR  
intensitie
s in Solid 
Cancers  
intensitie
s in 
Normal 
Tissues  
Fold 
change 
microRNA 
Chromosomal 
location 
< 1e-07 
< 1e-
07 
967 617.9 1.57 miR-21 17q23.1 
< 1e-07 
< 1e-
07 
1378.2 917.7 1.5 miR-25 7q22.1 
< 1e-07 
< 1e-
07 
902.7 626.3 1.44 miR-20a 13q31.3 
< 1e-07 
< 1e-
07 
925.7 646.9 1.43 miR-17 13q31.3 
< 1e-07 
< 1e-
07 
652.3 469 1.39 miR-106a Xq26.2 
< 1e-07 
< 1e-
07 
410 297.8 1.38 miR-106b 7q22.1 
1.30E-06 
1.08E-
05 
918.8 697.9 1.32 miR-146a 5q34 
< 1e-07 
< 1e-
07 
11893.3 9370.9 1.27 miR-92a 13q31.3,Xq26.2 
1.60E-06 
1.29E-
05 
2354.9 1919.4 1.23 miR-103 5q35.1,20p13 
< 1e-07 
< 1e-
07 
289.4 237.8 1.22 miR-130b 22q11.21 
6.81E-05 
0.0003
87 
750.4 615.7 1.22 miR-30c 1p34.2,6q13 
< 1e-07 
< 1e-
07 
452.7 372 1.22 miR-93 7q22.1 
3.90E-06 
2.74E-
05 
2116.4 1743.6 1.21 miR-107 10q23.31 
< 1e-07 
< 1e-
07 
297.7 248 1.2 miR-30e 1p34.2 
< 1e-07 
< 1e-
07 
227 191.9 1.18 miR-15a 13q14.2 
0.000433 0.002 1209.2 1031.6 1.17 miR-181b 1q32.1,9q33.3 
< 1e-07 
< 1e-
07 
191.3 164.8 1.16 miR-15b 3q25.33 
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0.000605 
0.0026
48 
508.2 438.5 1.16 miR-181a 1q32.1,9q33.3 
0.000442 
0.0020
02 
333.8 287 1.16 miR-32 9q31.3 
5.10E-06 
3.40E-
05 
160 147.3 1.09 miR-345 14q32.2 
0.000494 0.0022 208.1 193.5 1.08 miR-34a 1p36.22 
0.000864 
0.0037
2 
154.1 146.2 1.05 miR-374a Xq13.2 
< 1e-07 
< 1e-
07 
275.7 403 0.68 miR-203 14q32.33 
< 1e-07 
< 1e-
07 
714.9 1015.1 0.7 miR-145 5q32 
0.000003 
2.23E-
05 
273.7 349.6 0.78 miR-205 1q32.2 
2.00E-07 
1.80E-
06 
382.5 471.2 0.81 miR-206 6p12.2 
< 1e-07 
< 1e-
07 
204 247.9 0.82 miR-33b 17p11.2 
3.70E-06 
2.67E-
05 
419.9 507.8 0.83 miR-193a 17q11.2 
0.000042 
0.0002
49 
175.1 208.5 0.84 miR-204 9q21.12 
< 1e-07 
< 1e-
07 
173.9 204.2 0.85 miR-143 5q32 
1.00E-07 
0.0000
01 
220.5 260.2 0.85 miR-326 11q13.4 
< 1e-07 
< 1e-
07 
150.2 176.9 0.85 miR-338 17q25.3 
< 1e-07 
< 1e-
07 
164.8 193.6 0.85 miR-9 
1q22,5q14.3, 
15q26.1 
0.000355 
0.0017
89 
190.6 220.4 0.86 miR-95 4p16.1 
7.40E-06 
4.82E-
05 
225.6 259.4 0.87 miR-138 16q13,3p21.33 
0.000435 0.002 160.4 183.8 0.87 miR-183 7q32.2 
< 1e-07 
< 1e-
07 
150.4 172.9 0.87 miR-202 10q26.3 
8.24E-05 
0.0004
58 
529.1 603.1 0.88 miR-128a 2q21.3,3p22.3 
0.000921 
0.0039
05 
617 694.2 0.89 miR-214 1q24.3 
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< 1e-07 
< 1e-
07 
139 153.9 0.9 miR-132 17p13.3 
< 1e-07 
< 1e-
07 
140.7 156.7 0.9 miR-299 14q32.31 
< 1e-07 
< 1e-
07 
140.7 154.8 0.91 miR-129 7q32.1,11p11.2 
2.00E-07 
1.80E-
06 
139.6 152.7 0.91 miR-133a 
18q11.2,20q13.
33 
< 1e-07 
< 1e-
07 
129.8 141.1 0.92 miR-139 11q13.4 
8.80E-06 
5.46E-
05 
153.4 165 0.93 miR-339 7p22.3 
4.50E-06 
3.08E-
05 
140 149.6 0.94 miR-1 
20q13.33,18q1
1.2 
9.68E-05 
0.0005
28 
140.4 149.6 0.94 miR-133b 6p12.2 
< 1e-07 
< 1e-
07 
129.7 137.8 0.94 miR-323 14q32.31 
0.000394 
0.0019
46 
144.7 152.7 0.95 miR-218 4p15.31,5q34 
0.000193 
0.0010
1 
130.2 133 0.98 miR-335 7q32.2 
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Table A7 Expression levels of tissue specific microRNAs in cancer and 
leukemia.  
Name Cancer Specificity Expression  IC Chromosomal location 
miR-369-3p OVARIAN 
ADENOCARCINOMA 
2737 3.95 14:101531935-
101532004  
miR-325 PANCREAS NON-
FUNCTIONING ENDOCRINE 
CANCER / INSULINOMA 
1625 / 365    3.67 X: 76225829-76225926  
miR-208 CC  / BCC / EPIDERMIS SCC 256/ 244 / 
418 
3.36 14:22,927,645-
22,927,715 
14:22,957,036-
22,957,112 
miR-190 TPC / HEPATOBLASTOMA 211 / 220 3.04 15: 63116156-63116240  
miR-184 AMoL / HEPATOBLASTOMA 
/TPC / MM 
448 / 324 / 
214 / 171 
3.01 15: 79502130-79502213  
miR-338-5p EPIDERMIS SCC / BCC / CC 1928 / 808 / 
472 
2.70 17: 79099683-79099749  
miR-105 HGSIL 234 2.57 X:151,311,347-
151,313,620 
miR-376c LYMPHOMA CUTANEOUS / 
EPIDERMIS SCC / MM 
1134 / 626 / 
1223 / 525 
2.50 14: 101506027-
101506092 
miR-302b EPIDERMIS SCC / 
LYMPHOMA CUTANEOUS 
336 / 110 2.48 4: 113569641-
113569713 
miR-299-5p HEPATOBLASTOMA / AMoL / 
TPC 
287 / 122 / 
148 
2.03 14: 101490131-
101490193  
miR-19a LYMPHOMA CUTANEOUS / 
CML 
388 /367 1.83 13: 92003145-92003226  
miR-200c AMoL / HEPATOBLASTOMA 4460 / 4138 1.99 12: 7072862-7072929  
miR-143 AMoL / HEPATOBLASTOMA 1043 / 1098 1.94 5: 148808481-
148808586  
miR-211 EPIDERMIS SCC / NSCLC 129 / 89 1.86 15: 31357235-31357344  
miR-374a BL SPORADIC / CML / APL 619 / 169 / 
212  
1.69 X: 73507121-73507192  
miR-339-5p BL ENDEMIC / BL SPORADIC  616 / 738 1.62 7: 1062569-1062662  
miR-148a LYMPHOMA CUTANEOUS 1161 1.64 7: 25989539-25989606  
miR-370 BREAST, DUCTAL, LOBULAR, 
MALE CARCINOMA 
157, 227, 239 1.69 14: 101377476-
101377550  
miR-199a-
5p 
HEPATOBLASTOMA 1122 1.52 19:10,789,102-
10,789,172 
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1:170,380,298-
170,380,407 
miR-215 KIDNEY CARCINOMA / 
HEPATOBLASTOMA 
7247 /2461 1.45 1: 220291195-
220291304  
miR-19b CML 232 1.33 13:90,801,447-
90,801,533 
X:133,131,367-
133,131,462 
miR-148b LYMPHOMA CUTANEOUS 657 1.39 12: 54731000-54731098  
miR-18a AMoL / FOLLICULAR 
ADENOMA 
166 / 76 1.38 13: 92003005-92003075  
miR-202 AMoL/ HEPATOBLASTOMA 362 / 287 1.32 10: 135061015-
135061124  
miR-205 AMoL / HEPATOBLASTOMA / 
LUNG SCC 
2029 / 2275 / 
2665  
1.31 1: 209605478-
209605587  
 
 
Table A8 List of 100 miR selected by class prediction method. 
MiRNAs 
hsa-let-7e 
hsa-let-7i 
hsa-miR-100 
hsa-miR-105* 
hsa-miR-106b 
hsa-miR-10a 
hsa-miR-122 
hsa-miR-122* 
hsa-miR-125a-3p 
hsa-miR-125b 
hsa-miR-128a 
hsa-miR-132* 
hsa-miR-134 
hsa-miR-136 
hsa-miR-138-1* 
hsa-miR-138 
hsa-miR-142-5p 
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hsa-miR-145 
hsa-miR-146a 
hsa-miR-149 
hsa-miR-150 
hsa-miR-155 
hsa-miR-15b 
hsa-miR-16 
hsa-miR-181a 
hsa-miR-181b 
hsa-miR-187 
hsa-miR-190b 
hsa-miR-192 
hsa-miR-193b 
hsa-miR-197 
hsa-miR-199b-3p 
hsa-miR-1 
hsa-miR-200b 
hsa-miR-200c 
hsa-miR-203 
hsa-miR-204 
hsa-miR-205 
hsa-miR-210 
hsa-miR-215 
hsa-miR-218 
hsa-miR-219-2-3p 
hsa-miR-223 
hsa-miR-224 
hsa-miR-22 
hsa-miR-23b 
hsa-miR-24 
hsa-miR-25* 
hsa-miR-26a-1* 
hsa-miR-26a-2* 
hsa-miR-26b* 
hsa-miR-27b 
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hsa-miR-29a* 
hsa-miR-29b-1* 
hsa-miR-29b-2* 
hsa-miR-29c 
hsa-miR-30b* 
hsa-miR-30c-1* 
hsa-miR-324-3p 
hsa-miR-32 
hsa-miR-330-5p 
hsa-miR-33b 
hsa-miR-342-3p 
hsa-miR-342-5p 
hsa-miR-345 
hsa-miR-346 
hsa-miR-34c-3p 
hsa-miR-361-5p 
hsa-miR-369-3p 
hsa-miR-371-5p 
hsa-miR-374a 
hsa-miR-374b 
hsa-miR-375 
hsa-miR-376b 
hsa-miR-383 
hsa-miR-410 
hsa-miR-412 
hsa-miR-421 
hsa-miR-424 
hsa-miR-433 
hsa-miR-484 
hsa-miR-486-5p 
hsa-miR-487a 
hsa-miR-487b 
hsa-miR-494 
hsa-miR-496 
hsa-miR-498 
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hsa-miR-499-3p 
hsa-miR-500* 
hsa-miR-516a-5p 
hsa-miR-517b 
hsa-miR-519b-3p 
hsa-miR-543 
hsa-miR-551b* 
hsa-miR-671-5p 
hsa-miR-93* 
hsa-miR-99a 
hsa-miR-99b 
hsa-miR-99b* 
hsa-miR-9 
 
  
100 
 
Table A9 List of 31 miRNAs selected using evaluator: CfsSubsetEval and as 
searcher: BestFirst -D1 -N5. 
UniqueID 
hsa-miR-105* 
hsa-miR-10a 
hsa-miR-122 
hsa-miR-122* 
hsa-miR-134 
hsa-miR-145 
hsa-miR-146a 
hsa-miR-15b 
hsa-miR-181a 
hsa-miR-192 
hsa-miR-193b 
hsa-miR-197 
hsa-miR-210 
hsa-miR-215 
hsa-miR-218 
hsa-miR-219-2-3p 
hsa-miR-223 
hsa-miR-30c-1* 
hsa-miR-330-5p 
hsa-miR-33b 
hsa-miR-342-3p 
hsa-miR-346 
hsa-miR-34c-3p 
hsa-miR-375 
hsa-miR-383 
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hsa-miR-494 
hsa-miR-496 
hsa-miR-9 
 
Table A10 List of 15 miRNAs selected. 
  
UniqueID 
hsa-let-7e 
hsa-miR-105* 
hsa-miR-10a 
hsa-miR-122 
hsa-miR-145 
hsa-miR-15b 
hsa-miR-193b 
hsa-miR-215 
hsa-miR-218 
hsa-miR-30c-1* 
hsa-miR-330-5p 
hsa-miR-34c-3p 
hsa-miR-375 
hsa-miR-383 
hsa-miR-9 
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Table A11 Array CGH datasets. 
GEO 
datasets 
# of  
samples 
Cancer type Platform 
GSE4659 32 AML GPL2873  
GSE6472 6 Nasopharyngeal carcinoma GPL2879 
GSE7077 4 Osteosarcoma GPL2879 
GSE7344 16 Glioma GPL2873 
GSE7482  25 ACC GPL2879 
GSE7615 298 Pancreas, glioblastoma, T-ALL, 
melanoma, colon 
GPL2879 
GPL4091 
GSE7822 14 Melanoma GPL2879 
GSE8398 25 Ewing Sarcoma GPL2879 
GSE8804  13 Myelodysplasia GPL2879 
GSE8918 87 Follicular Lymphoma, CLL, Mantle Cell 
Lymphoma, Nodal Marginal Zone 
Lymphoma, Lymphoplasmacytic 
Lymphoma, Splenic Marginal Zone 
Lymphoma , MALT  
GPL2879 
GSE9015 7 Breast GPL4091 
GSE9654 10 Osteosarcoma GPL2879 
SMD  207 Lung, Pancreas, Breast, Melanoma, 
Fibrous Histiocytoma 
Stanford 
 
• GPL2873 Agilent- Human Genome CGH Microarray 44A G4410A  
• GPL2879 Agilent- Human Genome CGH Microarray 44B G4410B  
• GPL4091 Agilent- Human Genome CGH Microarray 244A G4411B 
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Table A12. Expression levels are calculated as 2^(-ΔΔCT) using 18S rRNA as a 
reference. Average of at least three experiments, each PCR performed in triplicates. 
Standard errors (ERR.ST.) are reported. 
 
Sample Name uc.283plus uc.283plus uc.283plus AVERAGE ERR.ST 
Spleen 6.91855E-08 1.82593E-07 2.40273E-07 1.64017E-07 2.90144E-08 
SV 3.5482E-07 6.30583E-07 7.71458E-07 5.8562E-07 7.06424E-08 
Thymus 3.25623E-07 6.1807E-07 4.94822E-07 4.79505E-07 4.89413E-08 
 Lungs 1.62718E-06 1.08067E-06 3.6858E-07 1.02548E-06 2.1037E-07 
BM 6.44552E-08 3.48473E-07 3.75434E-07 2.62787E-07 5.74297E-08 
ES 1.63444E-05 2.09864E-05 1.01926E-05 1.58411E-05 1.80482E-06 
      
Sample Name miR-302 miR-302 miR-302 AVERAGE ERR.ST 
Spleen 9.48487E-07 1.72605E-06 2.02762E-06 1.56739E-06 1.85596E-07 
SV 7.29868E-08 2.40353E-09 8.50101E-08 5.34668E-08 1.48763E-08 
Thymus 1.00638E-06 7.11832E-07 1.24061E-06 9.86274E-07 8.8321E-08 
 Lungs 7.85065E-07 2.40986E-07 1.82429E-07 4.02827E-07 1.10773E-07 
BM 1.18112E-06 1.83193E-06 1.31968E-06 1.44424E-06 1.14273E-07 
ES 3.35274E-05 3.37314E-05 2.50494E-05 3.07694E-05 1.65158E-06 
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Table A13 Differentially expressed miRNAs in miR-155 leukemia transgenic mouse. 
Parametric  
FDR  
Intensity in 
miR-155 
Leukemia 
Intensity 
in            
Wt 
Fold 
Change  
miRNA  
p-value  
1.00E-06 2.31E-05 832.1 10.08 82.57 miR--224 
4.20E-06 5.67E-05 3426.09 132.36 25.89 miR--9 
1.00E-07 7.20E-06 21760.18 1005.44 21.64 miR--217 
5.70E-06 7.39E-05 3387.97 219.75 15.42 miR--131 
1.00E-07 7.20E-06 5334.39 375.03 14.22 miR--128b 
1.00E-07 7.20E-06 31460.89 2922.63 10.76 miR--181b 
2.00E-07 7.20E-06 17040.98 1615.73 10.55 miR--181c 
2.00E-07 7.20E-06 18356.22 1976.64 9.29 miR--128a 
1.28E-05 0.000148 759.87 2695.34 0.28 miR--140 
0.000659 0.003556 228.42 874.66 0.26 miR--135a 
3.69E-05 0.000332 8491.07 34327.47 0.25 miR--26a 
0.000128 0.000984 528.06 2433.76 0.22 miR--10a 
3.50E-06 5.55E-05 590.74 2779.66 0.21 miR--425 
0.000193 0.001351 514.05 2467.2 0.21 miR--340 
0.000474 0.002742 81.06 403.52 0.2 miR--24 
2.00E-06 3.78E-05 656.68 3304.56 0.2 miR--140 
0.000579 0.003178 30.24 196.77 0.15 miR--218 
2.55E-05 0.000243 1006.31 6657.6 0.15 miR--29b 
6.00E-07 1.62E-05 1007.33 7465.65 0.13 miR--29a 
2.54E-05 0.000243 357.49 3183.78 0.11 miR--29c 
< 1e-07 < 1e-07 2176.08 37081.81 0.06 miR--146 
2.70E-06 4.60E-05 3339.45 59257.53 0.06 miR--150 
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APPENDIX B 
 
ESC and IPS and Normal POOL 
=== Run information === 
Scheme:       weka.classifiers.trees.J48 -C 0.25 -M 2 
Relation:     UCRescIPSnormaldifferpool-weka.filters.supervised.attribute.AttributeSelection-
Eweka.attributeSelection.CfsSubsetEval-Sweka.attributeSelection.BestFirst -D 1 -N 5 
Instances:    90 
Attributes:   16 
              uc.283Plus 
              uc.262Minus 
              uc.153Plus 
              uc.192Plus 
              uc.478Minus 
              uc.240Plus 
              uc.246Minus 
              uc.445Plus 
              uc.420Minus 
              uc.20Plus 
              uc.117Minus 
              uc.263Plus 
              uc.341Plus 
              uc.185Plus 
              uc.8Plus 
              Class 
Test mode:    10-fold cross-validation 
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J48 pruned tree 
------------------ 
 
uc.283Plus <= 7.589: Normal differ (49.0/1.0) 
uc.283Plus > 7.589 
|   uc.192Plus <= 7.623 
|   |   uc.20Plus <= 7.878: INDUCED PLURIPOTENT STEM CELLS (5.0) 
|   |   uc.20Plus > 7.878 
|   |   |   uc.262Minus <= 10.494: EMBRYONIC STEM CELLS (24.0) 
|   |   |   uc.262Minus > 10.494 
|   |   |   |   uc.246Minus <= 7.307: EMBRYONIC STEM CELLS (2.0) 
|   |   |   |   uc.246Minus > 7.307: INDUCED PLURIPOTENT STEM CELLS (2.0) 
|   uc.192Plus > 7.623: INDUCED PLURIPOTENT STEM CELLS (8.0) 
 
Number of Leaves  :  6 
 
Size of the tree :  11 
 
Time taken to build model: 0.05 seconds 
 
Correctly Classified Instances          77               85.5556 % 
Incorrectly Classified Instances        13               14.4444 % 
Kappa statistic                          0.759  
Mean absolute error                      0.1024 
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Root mean squared error                  0.2978 
Relative absolute error                 25.5589 % 
Root relative squared error             66.6062 % 
Total Number of Instances               90      
 
=== Detailed Accuracy By Class === 
 
               TP Rate   FP Rate   Precision   Recall  F-Measure   ROC Area  Class 
                 0.741     0.095      0.769     0.741     0.755      0.858    ESC 
                 0.667     0.08       0.625     0.667     0.645      0.888    IPSC 
                 0.979     0.024      0.979     0.979     0.979      0.967    Normal differ 
Weighted Avg.    0.856     0.055      0.857     0.856     0.856      0.921 
 
=== Confusion Matrix === 
 
  a  b  c   <-- classified as 
 20  6  1 |  a = EMBRYONIC STEM CELLS 
  5 10  0 |  b = INDUCED PLURIPOTENT STEM CELLS 
  1  0 47 |  c = Normal differ 
 
 
ESC and NORMAL POOL 
=== Run information === 
 
Scheme:       weka.classifiers.trees.J48 -C 0.25 -M 2 
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Relation:     UCRescnormaldifferpool-weka.filters.supervised.attribute.AttributeSelection-
Eweka.attributeSelection.CfsSubsetEval-Sweka.attributeSelection.BestFirst -D 1 -N 5 
Instances:    75 
Attributes:   20 
              uc.10Minus 
              uc.283Plus 
              uc.305Minus 
              uc.20Minus 
              uc.142Minus 
              uc.453Minus 
              uc.172Minus 
              uc.44Plus 
              uc.230Plus 
              uc.309Minus 
              uc.362Minus 
              uc.473Plus 
              uc.229Minus 
              uc.300Minus 
              uc.20Plus 
              uc.34Minus 
              uc.73Plus 
              uc.8Plus 
              uc.426Plus 
              Class 
Test mode:    10-fold cross-validation 
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=== Classifier model (full training set) === 
 
J48 pruned tree 
------------------ 
 
uc.283Plus <= 7.589: Normal differ (49.0/1.0) 
uc.283Plus > 7.589: EMBRYONIC STEM CELLS (26.0) 
 
Number of Leaves  :  2 
 
Size of the tree :  3 
 
 
Time taken to build model: 0.03 seconds 
 
=== Stratified cross-validation === 
=== Summary === 
 
Correctly Classified Instances          73               97.3333 % 
Incorrectly Classified Instances         2                2.6667 % 
Kappa statistic                          0.9421 
Mean absolute error                      0.0393 
Root mean squared error                  0.1642 
Relative absolute error                  8.5077 % 
Root relative squared error             34.1622 % 
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Total Number of Instances               75      
 
=== Detailed Accuracy By Class === 
               TP Rate   FP Rate   Precision   Recall  F-Measure   ROC Area  Class 
                 0.963     0.021      0.963     0.963     0.963      0.955    EMBRYONIC STEM CELLS 
                 0.979     0.037      0.979     0.979     0.979      0.955    Normal differ 
Weighted Avg.    0.973     0.031      0.973     0.973     0.973      0.955 
 
=== Confusion Matrix === 
  a  b   <-- classified as 
 26  1 |  a = EMBRYONIC STEM CELLS 
  1 47 |  b = Normal differ 
=== Run information === 
 
Scheme:weka.classifiers.trees.J48graft -C 0.25 -M 2 
Relation:     TrainingData323SOLIDnoADENO48miR-weka.filters.unsupervised.attribute 
 Instances:    140 
Attributes:   32 
              hsa-let-7e 
              hsa-let-7i 
              hsa-miR-100 
              hsa-miR-105* 
              hsa-miR-10a 
              hsa-miR-122 
              hsa-miR-122* 
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              hsa-miR-134 
              hsa-miR-145 
              hsa-miR-146a 
              hsa-miR-15b 
              hsa-miR-181a 
              hsa-miR-192 
              hsa-miR-193b 
              hsa-miR-197 
              hsa-miR-210 
              hsa-miR-215 
              hsa-miR-218 
              hsa-miR-219-2-3p 
              hsa-miR-223 
              hsa-miR-30c-1* 
              hsa-miR-330-5p 
              hsa-miR-33b 
              hsa-miR-342-3p 
              hsa-miR-346 
              hsa-miR-34c-3p 
              hsa-miR-375 
              hsa-miR-383 
              hsa-miR-494 
              hsa-miR-496 
              hsa-miR-9 
              Class 
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Test mode: evaluate on training data 
 
=== Classifier model (full training set) === 
 
J48graft pruned tree 
------------------ 
 
hsa-miR-218 <= 6.834 
|   hsa-miR-197 <= 8.748 
|   |   hsa-miR-346 <= 10.961: OVARIAN CARCINOMA (5.0/1.0) 
|   |   hsa-miR-346 > 10.961: LUNG SQUAMOUS CELL CARCINOMA (11.0/1.0) 
|   hsa-miR-197 > 8.748 
|   |   hsa-miR-192 <= 10.442 
|   |   |   hsa-miR-100 <= 10.586 
|   |   |   |   hsa-miR-383 <= 9.043 
|   |   |   |   |   hsa-miR-496 <= 6.339 
|   |   |   |   |   |   hsa-miR-30c-1* <= 6.94 
|   |   |   |   |   |   |   hsa-miR-181a <= 9.372 
|   |   |   |   |   |   |   |   hsa-miR-346 <= 6.0355: PROSTATE CARCINOMA (0.0|6.0) 
|   |   |   |   |   |   |   |   hsa-miR-346 > 6.0355 
|   |   |   |   |   |   |   |   |   hsa-miR-146a <= 3.944: PROSTATE CARCINOMA (0.0|6.0) 
|   |   |   |   |   |   |   |   |   hsa-miR-146a > 3.944 
|   |   |   |   |   |   |   |   |   |   hsa-miR-193b <= 9.3575 
|   |   |   |   |   |   |   |   |   |   |   hsa-miR-122* <= 5.8315 
|   |   |   |   |   |   |   |   |   |   |   |   hsa-miR-122 <= 11.4875 
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|   |   |   |   |   |   |   |   |   |   |   |   |   hsa-miR-122 <= 3.944: PROSTATE CARCINOMA (0.0|5.0) 
|   |   |   |   |   |   |   |   |   |   |   |   |   hsa-miR-122 > 3.944: ESOPHAGUS CARCINOMA (2.0/1.0) 
|   |   |   |   |   |   |   |   |   |   |   |   hsa-miR-122 > 11.4875: HEPATOCELLULAR CARCINOMA (0.0|5.0) 
|   |   |   |   |   |   |   |   |   |   |   hsa-miR-122* > 5.8315: HEPATOCELLULAR CARCINOMA (0.0|5.0) 
|   |   |   |   |   |   |   |   |   |   hsa-miR-193b > 9.3575: PROSTATE CARCINOMA (0.0|5.0) 
|   |   |   |   |   |   |   hsa-miR-181a > 9.372: BREAST CARCINOMA (7.0) 
|   |   |   |   |   |   hsa-miR-30c-1* > 6.94: ESOPHAGUS CARCINOMA (9.0) 
|   |   |   |   |   hsa-miR-496 > 6.339 
|   |   |   |   |   |   hsa-miR-105* <= 5.412: COLON CARCINOMA (3.0/1.0) 
|   |   |   |   |   |   hsa-miR-105* > 5.412: BLADDER CANCER (10.0/1.0) 
|   |   |   |   hsa-miR-383 > 9.043: MELANOMA (10.0/1.0) 
|   |   |   hsa-miR-100 > 10.586 
|   |   |   |   hsa-miR-342-3p <= 11.704 
|   |   |   |   |   hsa-miR-100 <= 13.359 
|   |   |   |   |   |   hsa-miR-146a <= 4.872: NSCLC (5.0) 
|   |   |   |   |   |   hsa-miR-146a > 4.872 
|   |   |   |   |   |   |   hsa-miR-383 <= 9.003 
|   |   |   |   |   |   |   |   hsa-miR-375 <= 8.849: BREAST CARCINOMA (2.0/1.0) 
|   |   |   |   |   |   |   |   hsa-miR-375 > 8.849: MELANOMA (0.0|5.0) 
|   |   |   |   |   |   |   hsa-miR-383 > 9.003: MELANOMA (0.0|9.0) 
|   |   |   |   |   hsa-miR-100 > 13.359: GLIOMA (4.0) 
|   |   |   |   hsa-miR-342-3p > 11.704: PROSTATE CARCINOMA (10.0) 
|   |   hsa-miR-192 > 10.442 
|   |   |   hsa-miR-122* <= 5.432 
|   |   |   |   hsa-miR-330-5p <= 4.55: GASTRIC CANCER (9.0) 
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|   |   |   |   hsa-miR-330-5p > 4.55: COLON CARCINOMA (6.0) 
|   |   |   hsa-miR-122* > 5.432: HEPATOCELLULAR CARCINOMA (9.0) 
hsa-miR-218 > 6.834 
|   hsa-miR-375 <= 8.633 
|   |   hsa-miR-145 <= 9.173 
|   |   |   hsa-miR-375 <= 5.946: GLIOMA (4.0) 
|   |   |   hsa-miR-375 > 5.946 
|   |   |   |   hsa-miR-100 <= 11.794 
|   |   |   |   |   hsa-miR-223 <= 3.528 
|   |   |   |   |   |   hsa-miR-181a <= 9.7665: OVARIAN CARCINOMA (0.0|5.0) 
|   |   |   |   |   |   hsa-miR-181a > 9.7665: GLIOMA (2.0/1.0) 
|   |   |   |   |   hsa-miR-223 > 3.528: OVARIAN CARCINOMA (5.0) 
|   |   |   |   hsa-miR-100 > 11.794: NSCLC (4.0) 
|   |   hsa-miR-145 > 9.173 
|   |   |   hsa-miR-219-2-3p <= 8.017 
|   |   |   |   hsa-let-7e <= 9.8775: GLIOMA (2.0/1.0) 
|   |   |   |   hsa-let-7e > 9.8775: KIDNEY CARCINOMA (0.0|5.0) 
|   |   |   hsa-miR-219-2-3p > 8.017: KIDNEY CARCINOMA (10.0/1.0) 
|   hsa-miR-375 > 8.633: PANCREAS CARCINOMA (11.0/1.0) 
 
Number of Leaves  :  32 
 
Size of the tree :  63 
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Time taken to build model: 0.08 seconds 
 
=== Evaluation on training set === 
=== Summary === 
 
Correctly Classified Instances         129               92.1429 % 
Incorrectly Classified Instances        11                7.8571 % 
Kappa statistic                          0.9154 
Mean absolute error                      0.0163 
Root mean squared error                  0.0903 
Relative absolute error                 12.2844 % 
Root relative squared error             35.0491 % 
Total Number of Instances              140      
 
=== Detailed Accuracy By Class === 
 
               TP Rate   FP Rate   Precision   Recall  F-Measure   ROC Area  Class 
                 0.9       0.008      0.9       0.9       0.9        0.992    BLADDER CANCER 
                 0.8       0.008      0.889     0.8       0.842      0.992    BREAST CARCINOMA 
                 0.8       0.008      0.889     0.8       0.842      0.993    COLON CARCINOMA 
                 1         0.008      0.909     1         0.952      1        ESOPHAGUS CARCINOMA 
                 0.9       0          1         0.9       0.947      1        GASTRIC CANCER 
                 1         0.015      0.833     1         0.909      0.998    GLIOMA 
                 0.9       0          1         0.9       0.947      1        HEPATOCELLULAR CARCINOMA 
                 0.9       0.008      0.9       0.9       0.9        0.992    KIDNEY CARCINOMA 
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                 1         0.008      0.909     1         0.952      0.996    LUNG SQUAMOUS CELL CARCINOMA 
                 0.9       0.008      0.9       0.9       0.9        0.994    MELANOMA 
                 0.9       0          1         0.9       0.947      1        NSCLC 
                 0.9       0.008      0.9       0.9       0.9        0.994    OVARIAN CARCINOMA 
                 1         0.008      0.909     1         0.952      0.996    PANCREAS CARCINOMA 
                 1         0          1         1         1          1        PROSTATE CARCINOMA 
Weighted Avg.    0.921     0.006      0.924     0.921     0.921      0.996 
 
 
 
 
 
 
 
 
=== Confusion Matrix === 
 
  a  b  c  d  e  f  g  h  i  j  k  l  m  n   <-- classified as 
  9  0  0  0  0  0  0  0  0  1  0  0  0  0 |  a = BLADDER CANCER 
  1  8  1  0  0  0  0  0  0  0  0  0  0  0 |  b = BREAST CARCINOMA 
  0  1  8  0  0  0  0  0  1  0  0  0  0  0 |  c = COLON CARCINOMA 
  0  0  0 10  0  0  0  0  0  0  0  0  0  0 |  d = ESOPHAGUS CARCINOMA 
  0  0  0  1  9  0  0  0  0  0  0  0  0  0 |  e = GASTRIC CANCER 
  0  0  0  0  0 10  0  0  0  0  0  0  0  0 |  f = GLIOMA 
  0  0  0  0  0  1  9  0  0  0  0  0  0  0 |  g = HEPATOCELLULAR CARCINOMA 
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  0  0  0  0  0  0  0  9  0  0  0  0  1  0 |  h = KIDNEY CARCINOMA 
  0  0  0  0  0  0  0  0 10  0  0  0  0  0 |  i = LUNG SQUAMOUS CELL CARCINOMA 
  0  0  0  0  0  0  0  0  0  9  0  1  0  0 |  j = MELANOMA 
  0  0  0  0  0  1  0  0  0  0  9  0  0  0 |  k = NSCLC 
  0  0  0  0  0  0  0  1  0  0  0  9  0  0 |  l = OVARIAN CARCINOMA 
  0  0  0  0  0  0  0  0  0  0  0  0 10  0 |  m = PANCREAS CARCINOMA 
  0  0  0  0  0  0  0  0  0  0  0  0  0 10 |  n = PROSTATE CARCINOMA 
 
=== Run information === 
 
Scheme:weka.classifiers.trees.J48graft -C 0.25 -M 2 
Relation:     TrainingData323SOLIDnoADENO48miR-weka.filters.unsupervised.attribute. 
Instances:    140 
Attributes:   32 
              hsa-let-7e 
              hsa-let-7i 
              hsa-miR-100 
              hsa-miR-105* 
              hsa-miR-10a 
              hsa-miR-122 
              hsa-miR-122* 
              hsa-miR-134 
              hsa-miR-145 
              hsa-miR-146a 
              hsa-miR-15b 
              hsa-miR-181a 
              hsa-miR-192 
              hsa-miR-193b 
              hsa-miR-197 
              hsa-miR-210 
              hsa-miR-215 
              hsa-miR-218 
              hsa-miR-219-2-3p 
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              hsa-miR-223 
              hsa-miR-30c-1* 
              hsa-miR-330-5p 
              hsa-miR-33b 
              hsa-miR-342-3p 
              hsa-miR-346 
              hsa-miR-34c-3p 
              hsa-miR-375 
              hsa-miR-383 
              hsa-miR-494 
              hsa-miR-496 
              hsa-miR-9 
              Class 
Test mode:user supplied test set: size unknown (reading incrementally) 
 
=== Classifier model (full training set) === 
 
J48graft pruned tree 
------------------ 
 
hsa-miR-218 <= 6.834 
|   hsa-miR-197 <= 8.748 
|   |   hsa-miR-346 <= 10.961: OVARIAN CARCINOMA (5.0/1.0) 
|   |   hsa-miR-346 > 10.961: LUNG SQUAMOUS CELL CARCINOMA (11.0/1.0) 
|   hsa-miR-197 > 8.748 
|   |   hsa-miR-192 <= 10.442 
|   |   |   hsa-miR-100 <= 10.586 
|   |   |   |   hsa-miR-383 <= 9.043 
|   |   |   |   |   hsa-miR-496 <= 6.339 
|   |   |   |   |   |   hsa-miR-30c-1* <= 6.94 
|   |   |   |   |   |   |   hsa-miR-181a <= 9.372 
|   |   |   |   |   |   |   |   hsa-miR-346 <= 6.0355: PROSTATE CARCINOMA (0.0|6.0) 
|   |   |   |   |   |   |   |   hsa-miR-346 > 6.0355 
|   |   |   |   |   |   |   |   |   hsa-miR-146a <= 3.944: PROSTATE CARCINOMA (0.0|6.0) 
|   |   |   |   |   |   |   |   |   hsa-miR-146a > 3.944 
|   |   |   |   |   |   |   |   |   |   hsa-miR-193b <= 9.3575 
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|   |   |   |   |   |   |   |   |   |   |   hsa-miR-122* <= 5.8315 
|   |   |   |   |   |   |   |   |   |   |   |   hsa-miR-122 <= 11.4875 
|   |   |   |   |   |   |   |   |   |   |   |   |   hsa-miR-122 <= 3.944: PROSTATE CARCINOMA (0.0|5.0) 
|   |   |   |   |   |   |   |   |   |   |   |   |   hsa-miR-122 > 3.944: ESOPHAGUS CARCINOMA (2.0/1.0) 
|   |   |   |   |   |   |   |   |   |   |   |   hsa-miR-122 > 11.4875: HEPATOCELLULAR CARCINOMA (0.0|5.0) 
|   |   |   |   |   |   |   |   |   |   |   hsa-miR-122* > 5.8315: HEPATOCELLULAR CARCINOMA (0.0|5.0) 
|   |   |   |   |   |   |   |   |   |   hsa-miR-193b > 9.3575: PROSTATE CARCINOMA (0.0|5.0) 
|   |   |   |   |   |   |   hsa-miR-181a > 9.372: BREAST CARCINOMA (7.0) 
|   |   |   |   |   |   hsa-miR-30c-1* > 6.94: ESOPHAGUS CARCINOMA (9.0) 
|   |   |   |   |   hsa-miR-496 > 6.339 
|   |   |   |   |   |   hsa-miR-105* <= 5.412: COLON CARCINOMA (3.0/1.0) 
|   |   |   |   |   |   hsa-miR-105* > 5.412: BLADDER CANCER (10.0/1.0) 
|   |   |   |   hsa-miR-383 > 9.043: MELANOMA (10.0/1.0) 
|   |   |   hsa-miR-100 > 10.586 
|   |   |   |   hsa-miR-342-3p <= 11.704 
|   |   |   |   |   hsa-miR-100 <= 13.359 
|   |   |   |   |   |   hsa-miR-146a <= 4.872: NSCLC (5.0) 
|   |   |   |   |   |   hsa-miR-146a > 4.872 
|   |   |   |   |   |   |   hsa-miR-383 <= 9.003 
|   |   |   |   |   |   |   |   hsa-miR-375 <= 8.849: BREAST CARCINOMA (2.0/1.0) 
|   |   |   |   |   |   |   |   hsa-miR-375 > 8.849: MELANOMA (0.0|5.0) 
|   |   |   |   |   |   |   hsa-miR-383 > 9.003: MELANOMA (0.0|9.0) 
|   |   |   |   |   hsa-miR-100 > 13.359: GLIOMA (4.0) 
|   |   |   |   hsa-miR-342-3p > 11.704: PROSTATE CARCINOMA (10.0) 
|   |   hsa-miR-192 > 10.442 
|   |   |   hsa-miR-122* <= 5.432 
|   |   |   |   hsa-miR-330-5p <= 4.55: GASTRIC CANCER (9.0) 
|   |   |   |   hsa-miR-330-5p > 4.55: COLON CARCINOMA (6.0) 
|   |   |   hsa-miR-122* > 5.432: HEPATOCELLULAR CARCINOMA (9.0) 
hsa-miR-218 > 6.834 
|   hsa-miR-375 <= 8.633 
|   |   hsa-miR-145 <= 9.173 
|   |   |   hsa-miR-375 <= 5.946: GLIOMA (4.0) 
|   |   |   hsa-miR-375 > 5.946 
|   |   |   |   hsa-miR-100 <= 11.794 
|   |   |   |   |   hsa-miR-223 <= 3.528 
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|   |   |   |   |   |   hsa-miR-181a <= 9.7665: OVARIAN CARCINOMA (0.0|5.0) 
|   |   |   |   |   |   hsa-miR-181a > 9.7665: GLIOMA (2.0/1.0) 
|   |   |   |   |   hsa-miR-223 > 3.528: OVARIAN CARCINOMA (5.0) 
|   |   |   |   hsa-miR-100 > 11.794: NSCLC (4.0) 
|   |   hsa-miR-145 > 9.173 
|   |   |   hsa-miR-219-2-3p <= 8.017 
|   |   |   |   hsa-let-7e <= 9.8775: GLIOMA (2.0/1.0) 
|   |   |   |   hsa-let-7e > 9.8775: KIDNEY CARCINOMA (0.0|5.0) 
|   |   |   hsa-miR-219-2-3p > 8.017: KIDNEY CARCINOMA (10.0/1.0) 
|   hsa-miR-375 > 8.633: PANCREAS CARCINOMA (11.0/1.0) 
 
Number of Leaves  :  32 
 
Size of the tree :  63 
 
 
Time taken to build model: 0.09 seconds 
 
=== Predictions on test split === 
 
inst#,    actual, predicted, error, probability distribution 
     1 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     2 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     3 1:BLADDER  10:MELANOM      +   0.1    0      0      0      0      0      0      0      0     *0.9    0      0      0      
0     
     4 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     5 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     6 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     7 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
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     8 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     9 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
    10 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
    11 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    12 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    13 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    14 2:BREAST C 3:COLON CA      +   0      0.333 *0.667  0      0      0      0      0      0      0      0      0      
0      0     
    15 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    16 2:BREAST C 2:BREAST C          0     *0.5    0.5    0      0      0      0      0      0      0      0      0      0      
0     
    17 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    18 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    19 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    20 2:BREAST C 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
    21 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    22 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    23 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    24 3:COLON CA 2:BREAST C      +   0     *0.5    0.5    0      0      0      0      0      0      0      0      0      0      
0     
    25 3:COLON CA 3:COLON CA          0      0.333 *0.667  0      0      0      0      0      0      0      0      0      
0      0     
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    26 3:COLON CA 9:LUNG SQU      +   0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
    27 3:COLON CA 3:COLON CA          0      0.333 *0.667  0      0      0      0      0      0      0      0      0      
0      0     
    28 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    29 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    30 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    31 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    32 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    33 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    34 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    35 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    36 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *0.5    0.5    0      0      0      0      0      0      0      
0      0     
    37 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    38 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    39 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    40 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    41 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    42 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    43 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
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    44 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    45 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    46 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    47 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    48 5:GASTRIC  4:ESOPHAGU      +   0      0      0     *0.5    0.5    0      0      0      0      0      0      0      0      
0     
    49 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    50 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    51   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *0.5    0.5    0      0      0      0      0      0      
0     
    52   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *0.5    0      0      0      0      0.5    0      0      
0     
    53   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    54   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    55   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    56   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    57   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    58   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    59   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    60   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    61 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    62 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    63 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    64 7:HEPATOCE   6:GLIOMA      +   0      0      0      0      0     *0.5    0.5    0      0      0      0      0      0      
0     
    65 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
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    66 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    67 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    68 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    69 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    70 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    71 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    72 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    73 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    74 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    75 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    76 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    77 8:KIDNEY C 13:PANCREA      +   0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
    78 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    79 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    80 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    81 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
    82 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
    83 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
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    84 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
    85 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
    86 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
    87 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
    88 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
    89 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
    90 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
    91 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
    92 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
    93 10:MELANOM 12:OVARIAN      +   0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
    94 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
    95 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
    96 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
    97 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
    98 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
    99 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
   100 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
   101   11:NSCLC   6:GLIOMA      +   0      0      0      0      0     *0.5    0      0      0      0      0.5    0      0      
0     
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   102   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   103   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   104   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   105   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   106   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   107   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   108   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   109   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   110   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   111 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
   112 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
   113 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
   114 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
   115 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   116 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   117 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   118 12:OVARIAN 8:KIDNEY C      +   0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   119 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   120 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   121 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   122 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   123 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
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   124 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   125 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   126 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   127 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   128 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   129 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   130 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   131 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   132 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   133 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   134 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   135 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   136 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   137 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   138 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   139 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   140 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   141 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
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   142 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   143 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   144 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   145 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   146 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   147 1:BLADDER  4:ESOPHAGU      +   0      0      0     *0.5    0.5    0      0      0      0      0      0      0      
0      0     
   148 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   149 1:BLADDER  4:ESOPHAGU      +   0      0      0     *0.5    0.5    0      0      0      0      0      0      0      
0      0     
   150 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   151 2:BREAST C 14:PROSTAT      +   0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   152 2:BREAST C 12:OVARIAN      +   0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
   153 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
   154 2:BREAST C 12:OVARIAN      +   0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
   155 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
   156 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
   157 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
   158 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
   159 2:BREAST C 4:ESOPHAGU      +   0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
129 
 
   160 2:BREAST C 14:PROSTAT      +   0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   161 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   162 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   163 3:COLON CA 12:OVARIAN      +   0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
   164 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   165 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   166 3:COLON CA 3:COLON CA          0      0.333 *0.667  0      0      0      0      0      0      0      0      0      
0      0     
   167 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   168 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   169 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   170 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   171 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   172 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   173 4:ESOPHAGU 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      
0      0     
   174 4:ESOPHAGU 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      
0      0     
   175 4:ESOPHAGU 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      
0      0     
   176 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   177 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
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   178 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   179 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   180 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   181 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   182 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   183 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   184 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   185 5:GASTRIC  7:HEPATOCE      +   0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   186 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   187 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   188 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   189 5:GASTRIC    6:GLIOMA      +   0      0      0      0      0     *0.5    0.5    0      0      0      0      0      0      
0     
   190 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   191   6:GLIOMA 2:BREAST C      +   0     *0.5    0.5    0      0      0      0      0      0      0      0      0      0      
0     
   192   6:GLIOMA 2:BREAST C      +   0     *0.5    0.5    0      0      0      0      0      0      0      0      0      0      
0     
   193   6:GLIOMA 2:BREAST C      +   0     *0.5    0.5    0      0      0      0      0      0      0      0      0      0      
0     
   194   6:GLIOMA 2:BREAST C      +   0     *0.5    0.5    0      0      0      0      0      0      0      0      0      0      
0     
   195   6:GLIOMA 2:BREAST C      +   0     *0.5    0.5    0      0      0      0      0      0      0      0      0      0      
0     
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   196   6:GLIOMA 2:BREAST C      +   0     *0.5    0.5    0      0      0      0      0      0      0      0      0      0      
0     
   197   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
   198   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
   199   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
   200   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
   201 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   202 7:HEPATOCE 5:GASTRIC       +   0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   203 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   204 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   205 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   206 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   207 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   208 7:HEPATOCE 5:GASTRIC       +   0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   209 7:HEPATOCE 13:PANCREA      +   0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   210 7:HEPATOCE 5:GASTRIC       +   0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   211 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   212 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   213 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   214 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   215 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
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   216 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   217 8:KIDNEY C   6:GLIOMA      +   0      0      0      0      0     *0.5    0.5    0      0      0      0      0      0      
0     
   218 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   219 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   220 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   221 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
   222 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
   223 9:LUNG SQU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   224 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
   225 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
   226 9:LUNG SQU 9:LUNG SQU          0      0      0.091  0      0      0      0      0     *0.909  0      0      0      
0      0     
   227 9:LUNG SQU 3:COLON CA      +   0      0.333 *0.667  0      0      0      0      0      0      0      0      0      
0      0     
   228 9:LUNG SQU 3:COLON CA      +   0      0.333 *0.667  0      0      0      0      0      0      0      0      0      
0      0     
   229 9:LUNG SQU 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   230 9:LUNG SQU 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   231 10:MELANOM 4:ESOPHAGU      +   0      0      0     *1      0      0      0      0      0      0      0      0      
0      0     
   232 10:MELANOM 5:GASTRIC       +   0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   233 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
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   234 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
   235 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
   236 10:MELANOM 4:ESOPHAGU      +   0      0      0     *1      0      0      0      0      0      0      0      0      
0      0     
   237 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
   238 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
   239 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
   240 10:MELANOM 10:MELANOM          0.1    0      0      0      0      0      0      0      0     *0.9    0      0      
0      0     
   241   11:NSCLC 12:OVARIAN      +   0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   242   11:NSCLC 12:OVARIAN      +   0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   243   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   244   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   245   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   246   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   247   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   248   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   249   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   250   11:NSCLC 2:BREAST C      +   0     *0.5    0.5    0      0      0      0      0      0      0      0      0      0      
0     
   251 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
   252 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
   253 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   254 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
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   255 12:OVARIAN 13:PANCREA      +   0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   256 12:OVARIAN 13:PANCREA      +   0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   257 12:OVARIAN 8:KIDNEY C      +   0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   258 12:OVARIAN 8:KIDNEY C      +   0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   259 12:OVARIAN 14:PROSTAT      +   0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   260 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
   261 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   262 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   263 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   264 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   265 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   266 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   267 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   268 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   269 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   270 13:PANCREA 8:KIDNEY C      +   0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   271 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   272 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
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   273 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   274 14:PROSTAT 13:PANCREA      +   0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   275 14:PROSTAT   6:GLIOMA      +   0      0      0      0      0     *1      0      0      0      0      0      0      0      
0     
   276 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   277 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   278 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   279 14:PROSTAT 12:OVARIAN      +   0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
   280 14:PROSTAT 12:OVARIAN      +   0      0      0      0      0      0      0      0      0      0.2    0     *0.8    0      
0     
 
=== Evaluation on test set === 
=== Summary === 
 
Correctly Classified Instances         217               77.5    % 
Incorrectly Classified Instances        63               22.5    % 
Kappa statistic                          0.7577 
Mean absolute error                      0.0369 
Root mean squared error                  0.168  
Relative absolute error                 27.7984 % 
Root relative squared error             65.2313 % 
Total Number of Instances              280      
 
=== Detailed Accuracy By Class === 
 
               TP Rate   FP Rate   Precision   Recall  F-Measure   ROC Area  Class 
                 0.85      0.023      0.739     0.85      0.791      0.933    BLADDER CANCER 
                 0.65      0.031      0.619     0.65      0.634      0.851    BREAST CARCINOMA 
                 0.85      0.042      0.607     0.85      0.708      0.948    COLON CARCINOMA 
                 0.5       0.023      0.625     0.5       0.556      0.741    ESOPHAGUS CARCINOMA 
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                 0.85      0.015      0.81      0.85      0.829      0.941    GASTRIC CANCER 
                 0.7       0.019      0.737     0.7       0.718      0.845    GLIOMA 
                 0.75      0.004      0.938     0.75      0.833      0.897    HEPATOCELLULAR CARCINOMA 
                 0.9       0.015      0.818     0.9       0.857      0.963    KIDNEY CARCINOMA 
                 0.75      0.004      0.938     0.75      0.833      0.873    LUNG SQUAMOUS CELL CARCINOMA 
                 0.8       0.004      0.941     0.8       0.865      0.918    MELANOMA 
                 0.8       0          1         0.8       0.889      0.925    NSCLC 
                 0.7       0.031      0.636     0.7       0.667      0.9      OVARIAN CARCINOMA 
                 0.95      0.019      0.792     0.95      0.864      0.965    PANCREAS CARCINOMA 
                 0.8       0.012      0.842     0.8       0.821      0.894    PROSTATE CARCINOMA 
Weighted Avg.    0.775     0.017      0.789     0.775     0.776      0.899 
 
=== Confusion Matrix === 
 
  a  b  c  d  e  f  g  h  i  j  k  l  m  n   <-- classified as 
 17  0  0  2  0  0  0  0  0  1  0  0  0  0 |  a = BLADDER CANCER 
  1 13  1  1  0  0  0  0  0  0  0  2  0  2 |  b = BREAST CARCINOMA 
  0  1 17  0  0  0  0  0  1  0  0  1  0  0 |  c = COLON CARCINOMA 
  3  0  7 10  0  0  0  0  0  0  0  0  0  0 |  d = ESOPHAGUS CARCINOMA 
  0  0  0  1 17  1  1  0  0  0  0  0  0  0 |  e = GASTRIC CANCER 
  0  6  0  0  0 14  0  0  0  0  0  0  0  0 |  f = GLIOMA 
  0  0  0  0  3  1 15  0  0  0  0  0  1  0 |  g = HEPATOCELLULAR CARCINOMA 
  0  0  0  0  0  1  0 18  0  0  0  0  1  0 |  h = KIDNEY CARCINOMA 
  2  0  3  0  0  0  0  0 15  0  0  0  0  0 |  i = LUNG SQUAMOUS CELL CARCINOMA 
  0  0  0  2  1  0  0  0  0 16  0  1  0  0 |  j = MELANOMA 
  0  1  0  0  0  1  0  0  0  0 16  2  0  0 |  k = NSCLC 
  0  0  0  0  0  0  0  3  0  0  0 14  2  1 |  l = OVARIAN CARCINOMA 
  0  0  0  0  0  0  0  1  0  0  0  0 19  0 |  m = PANCREAS CARCINOMA 
  0  0  0  0  0  1  0  0  0  0  0  2  1 16 |  n = PROSTATE CARCINOMA 
 
=== Run information === 
 
Scheme:weka.classifiers.trees.J48graft -C 0.25 -M 2 
Relation:     TrainingData323SOLIDnoADENO48miR-weka.filters.unsupervised.attribute.Remove-R2-
3,7-11,13,15-16,18-23,26-29,31-32,34-36,40-45,47 
Instances:    140 
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Attributes:   16 
              hsa-let-7e 
              hsa-miR-105* 
              hsa-miR-10a 
              hsa-miR-122 
              hsa-miR-145 
              hsa-miR-15b 
              hsa-miR-193b 
              hsa-miR-215 
              hsa-miR-218 
              hsa-miR-30c-1* 
              hsa-miR-330-5p 
              hsa-miR-34c-3p 
              hsa-miR-375 
              hsa-miR-383 
              hsa-miR-9 
              Class 
Test mode:evaluate on training data 
 
=== Classifier model (full training set) === 
 
J48graft pruned tree 
------------------ 
 
hsa-miR-218 <= 6.834 
|   hsa-miR-215 <= 10.152 
|   |   hsa-miR-383 <= 9.043 
|   |   |   hsa-miR-34c-3p <= 5.821 
|   |   |   |   hsa-miR-193b <= 8.367 
|   |   |   |   |   hsa-miR-383 <= 6.914 
|   |   |   |   |   |   hsa-let-7e <= 9.765: LUNG SQUAMOUS CELL CARCINOMA (8.0) 
|   |   |   |   |   |   hsa-let-7e > 9.765: GLIOMA (3.0) 
|   |   |   |   |   hsa-miR-383 > 6.914: ESOPHAGUS CARCINOMA (6.0/1.0) 
|   |   |   |   hsa-miR-193b > 8.367: PROSTATE CARCINOMA (11.0/1.0) 
|   |   |   hsa-miR-34c-3p > 5.821 
|   |   |   |   hsa-miR-30c-1* <= 9.066 
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|   |   |   |   |   hsa-miR-10a <= 9.198 
|   |   |   |   |   |   hsa-miR-122 <= 8.518: BLADDER CANCER (10.0/1.0) 
|   |   |   |   |   |   hsa-miR-122 > 8.518 
|   |   |   |   |   |   |   hsa-let-7e <= 7.8325: BLADDER CANCER (0.0|7.0) 
|   |   |   |   |   |   |   hsa-let-7e > 7.8325: BREAST CARCINOMA (3.0/1.0) 
|   |   |   |   |   hsa-miR-10a > 9.198 
|   |   |   |   |   |   hsa-miR-218 <= 3.565 
|   |   |   |   |   |   |   hsa-miR-30c-1* <= 7.097 
|   |   |   |   |   |   |   |   hsa-miR-15b <= 5.272: COLON CARCINOMA (2.0) 
|   |   |   |   |   |   |   |   hsa-miR-15b > 5.272: BREAST CARCINOMA (7.0) 
|   |   |   |   |   |   |   hsa-miR-30c-1* > 7.097 
|   |   |   |   |   |   |   |   hsa-miR-105* <= 6.507: ESOPHAGUS CARCINOMA (2.0) 
|   |   |   |   |   |   |   |   hsa-miR-105* > 6.507: LUNG SQUAMOUS CELL CARCINOMA (2.0) 
|   |   |   |   |   |   hsa-miR-218 > 3.565: NSCLC (6.0/1.0) 
|   |   |   |   hsa-miR-30c-1* > 9.066 
|   |   |   |   |   hsa-miR-105* <= 8.394: ESOPHAGUS CARCINOMA (2.0) 
|   |   |   |   |   hsa-miR-105* > 8.394: OVARIAN CARCINOMA (4.0) 
|   |   hsa-miR-383 > 9.043: MELANOMA (11.0/1.0) 
|   hsa-miR-215 > 10.152 
|   |   hsa-miR-330-5p <= 4.55 
|   |   |   hsa-miR-34c-3p <= 5.432: GASTRIC CANCER (9.0) 
|   |   |   hsa-miR-34c-3p > 5.432: HEPATOCELLULAR CARCINOMA (9.0) 
|   |   hsa-miR-330-5p > 4.55: COLON CARCINOMA (7.0) 
hsa-miR-218 > 6.834 
|   hsa-miR-375 <= 8.633 
|   |   hsa-miR-145 <= 9.173 
|   |   |   hsa-miR-375 <= 5.946: GLIOMA (4.0) 
|   |   |   hsa-miR-375 > 5.946 
|   |   |   |   hsa-let-7e <= 9.638 
|   |   |   |   |   hsa-miR-122 <= 7.79: OVARIAN CARCINOMA (2.0) 
|   |   |   |   |   hsa-miR-122 > 7.79: NSCLC (6.0/1.0) 
|   |   |   |   hsa-let-7e > 9.638: OVARIAN CARCINOMA (3.0) 
|   |   hsa-miR-145 > 9.173 
|   |   |   hsa-miR-193b <= 6.339: KIDNEY CARCINOMA (10.0/1.0) 
|   |   |   hsa-miR-193b > 6.339 
|   |   |   |   hsa-miR-330-5p <= 3.538: KIDNEY CARCINOMA (0.0|5.0) 
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|   |   |   |   hsa-miR-330-5p > 3.538: GLIOMA (2.0/1.0) 
|   hsa-miR-375 > 8.633: PANCREAS CARCINOMA (11.0/1.0) 
 
Number of Leaves  :  26 
 
Size of the tree :  51 
 
 
Time taken to build model: 0.05 seconds 
=== Evaluation on training set === 
=== Summary === 
 
Correctly Classified Instances         130               92.8571 % 
Incorrectly Classified Instances        10                7.1429 % 
Kappa statistic                          0.9231 
Mean absolute error                      0.0167 
Root mean squared error                  0.0914 
Relative absolute error                 12.6061 % 
Root relative squared error             35.505  % 
Total Number of Instances              140      
 
=== Detailed Accuracy By Class === 
 
               TP Rate   FP Rate   Precision   Recall  F-Measure   ROC Area  Class 
                 0.9       0.008      0.9       0.9       0.9        0.992    BLADDER CANCER 
                 0.9       0.008      0.9       0.9       0.9        0.995    BREAST CARCINOMA 
                 0.9       0          1         0.9       0.947      0.999    COLON CARCINOMA 
                 0.9       0.008      0.9       0.9       0.9        0.995    ESOPHAGUS CARCINOMA 
                 0.9       0          1         0.9       0.947      0.998    GASTRIC CANCER 
                 0.8       0.008      0.889     0.8       0.842      0.988    GLIOMA 
                 0.9       0          1         0.9       0.947      1        HEPATOCELLULAR CARCINOMA 
                 0.9       0.008      0.9       0.9       0.9        0.992    KIDNEY CARCINOMA 
                 1         0          1         1         1          1        LUNG SQUAMOUS CELL CARCINOMA 
                 1         0.008      0.909     1         0.952      0.996    MELANOMA 
                 1         0.015      0.833     1         0.909      0.992    NSCLC 
                 0.9       0          1         0.9       0.947      0.997    OVARIAN CARCINOMA 
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                 1         0.008      0.909     1         0.952      0.996    PANCREAS CARCINOMA 
                 1         0.008      0.909     1         0.952      0.996    PROSTATE CARCINOMA 
Weighted Avg.    0.929     0.005      0.932     0.929     0.928      0.995 
 
=== Confusion Matrix === 
 
  a  b  c  d  e  f  g  h  i  j  k  l  m  n   <-- classified as 
  9  0  0  0  0  0  0  0  0  1  0  0  0  0 |  a = BLADDER CANCER 
  1  9  0  0  0  0  0  0  0  0  0  0  0  0 |  b = BREAST CARCINOMA 
  0  1  9  0  0  0  0  0  0  0  0  0  0  0 |  c = COLON CARCINOMA 
  0  0  0  9  0  0  0  0  0  0  1  0  0  0 |  d = ESOPHAGUS CARCINOMA 
  0  0  0  1  9  0  0  0  0  0  0  0  0  0 |  e = GASTRIC CANCER 
  0  0  0  0  0  8  0  0  0  0  1  0  0  1 |  f = GLIOMA 
  0  0  0  0  0  1  9  0  0  0  0  0  0  0 |  g = HEPATOCELLULAR CARCINOMA 
  0  0  0  0  0  0  0  9  0  0  0  0  1  0 |  h = KIDNEY CARCINOMA 
  0  0  0  0  0  0  0  0 10  0  0  0  0  0 |  i = LUNG SQUAMOUS CELL CARCINOMA 
  0  0  0  0  0  0  0  0  0 10  0  0  0  0 |  j = MELANOMA 
  0  0  0  0  0  0  0  0  0  0 10  0  0  0 |  k = NSCLC 
  0  0  0  0  0  0  0  1  0  0  0  9  0  0 |  l = OVARIAN CARCINOMA 
  0  0  0  0  0  0  0  0  0  0  0  0 10  0 |  m = PANCREAS CARCINOMA 
  0  0  0  0  0  0  0  0  0  0  0  0  0 10 |  n = PROSTATE CARCINOMA 
 
== Run information === 
 
Scheme:weka.classifiers.trees.J48graft -C 0.25 -M 2 
Relation:     TrainingData323SOLIDnoADENO48miR-weka.filters.unsupervised.attribute.Remove-R2-
3,7-11,13,15-16,18-23,26-29,31-32,34-36,40-45,47 
Instances:    140 
Attributes:   16 
              hsa-let-7e 
              hsa-miR-105* 
              hsa-miR-10a 
              hsa-miR-122 
              hsa-miR-145 
              hsa-miR-15b 
              hsa-miR-193b 
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              hsa-miR-215 
              hsa-miR-218 
              hsa-miR-30c-1* 
              hsa-miR-330-5p 
              hsa-miR-34c-3p 
              hsa-miR-375 
              hsa-miR-383 
              hsa-miR-9 
              Class 
Test mode:user supplied test set: size unknown (reading incrementally) 
 
=== Classifier model (full training set) === 
 
J48graft pruned tree 
------------------ 
 
hsa-miR-218 <= 6.834 
|   hsa-miR-215 <= 10.152 
|   |   hsa-miR-383 <= 9.043 
|   |   |   hsa-miR-34c-3p <= 5.821 
|   |   |   |   hsa-miR-193b <= 8.367 
|   |   |   |   |   hsa-miR-383 <= 6.914 
|   |   |   |   |   |   hsa-let-7e <= 9.765: LUNG SQUAMOUS CELL CARCINOMA (8.0) 
|   |   |   |   |   |   hsa-let-7e > 9.765: GLIOMA (3.0) 
|   |   |   |   |   hsa-miR-383 > 6.914: ESOPHAGUS CARCINOMA (6.0/1.0) 
|   |   |   |   hsa-miR-193b > 8.367: PROSTATE CARCINOMA (11.0/1.0) 
|   |   |   hsa-miR-34c-3p > 5.821 
|   |   |   |   hsa-miR-30c-1* <= 9.066 
|   |   |   |   |   hsa-miR-10a <= 9.198 
|   |   |   |   |   |   hsa-miR-122 <= 8.518: BLADDER CANCER (10.0/1.0) 
|   |   |   |   |   |   hsa-miR-122 > 8.518 
|   |   |   |   |   |   |   hsa-let-7e <= 7.8325: BLADDER CANCER (0.0|7.0) 
|   |   |   |   |   |   |   hsa-let-7e > 7.8325: BREAST CARCINOMA (3.0/1.0) 
|   |   |   |   |   hsa-miR-10a > 9.198 
|   |   |   |   |   |   hsa-miR-218 <= 3.565 
|   |   |   |   |   |   |   hsa-miR-30c-1* <= 7.097 
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|   |   |   |   |   |   |   |   hsa-miR-15b <= 5.272: COLON CARCINOMA (2.0) 
|   |   |   |   |   |   |   |   hsa-miR-15b > 5.272: BREAST CARCINOMA (7.0) 
|   |   |   |   |   |   |   hsa-miR-30c-1* > 7.097 
|   |   |   |   |   |   |   |   hsa-miR-105* <= 6.507: ESOPHAGUS CARCINOMA (2.0) 
|   |   |   |   |   |   |   |   hsa-miR-105* > 6.507: LUNG SQUAMOUS CELL CARCINOMA (2.0) 
|   |   |   |   |   |   hsa-miR-218 > 3.565: NSCLC (6.0/1.0) 
|   |   |   |   hsa-miR-30c-1* > 9.066 
|   |   |   |   |   hsa-miR-105* <= 8.394: ESOPHAGUS CARCINOMA (2.0) 
|   |   |   |   |   hsa-miR-105* > 8.394: OVARIAN CARCINOMA (4.0) 
|   |   hsa-miR-383 > 9.043: MELANOMA (11.0/1.0) 
|   hsa-miR-215 > 10.152 
|   |   hsa-miR-330-5p <= 4.55 
|   |   |   hsa-miR-34c-3p <= 5.432: GASTRIC CANCER (9.0) 
|   |   |   hsa-miR-34c-3p > 5.432: HEPATOCELLULAR CARCINOMA (9.0) 
|   |   hsa-miR-330-5p > 4.55: COLON CARCINOMA (7.0) 
hsa-miR-218 > 6.834 
|   hsa-miR-375 <= 8.633 
|   |   hsa-miR-145 <= 9.173 
|   |   |   hsa-miR-375 <= 5.946: GLIOMA (4.0) 
|   |   |   hsa-miR-375 > 5.946 
|   |   |   |   hsa-let-7e <= 9.638 
|   |   |   |   |   hsa-miR-122 <= 7.79: OVARIAN CARCINOMA (2.0) 
|   |   |   |   |   hsa-miR-122 > 7.79: NSCLC (6.0/1.0) 
|   |   |   |   hsa-let-7e > 9.638: OVARIAN CARCINOMA (3.0) 
|   |   hsa-miR-145 > 9.173 
|   |   |   hsa-miR-193b <= 6.339: KIDNEY CARCINOMA (10.0/1.0) 
|   |   |   hsa-miR-193b > 6.339 
|   |   |   |   hsa-miR-330-5p <= 3.538: KIDNEY CARCINOMA (0.0|5.0) 
|   |   |   |   hsa-miR-330-5p > 3.538: GLIOMA (2.0/1.0) 
|   hsa-miR-375 > 8.633: PANCREAS CARCINOMA (11.0/1.0) 
 
Number of Leaves  :  26 
 
Size of the tree :  51 
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Time taken to build model: 0.05 seconds 
 
=== Predictions on test split === 
 
inst#,    actual, predicted, error, probability distribution 
     1 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     2 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     3 1:BLADDER  10:MELANOM      +   0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
     4 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     5 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     6 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     7 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     8 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
     9 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
    10 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
    11 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    12 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    13 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    14 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    15 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
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    16 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    17 2:BREAST C 2:BREAST C          0     *0.667  0.333  0      0      0      0      0      0      0      0      0      
0      0     
    18 2:BREAST C 2:BREAST C          0     *0.667  0.333  0      0      0      0      0      0      0      0      0      
0      0     
    19 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
    20 2:BREAST C 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
    21 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    22 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    23 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    24 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    25 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    26 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    27 3:COLON CA 2:BREAST C      +   0     *0.667  0.333  0      0      0      0      0      0      0      0      0      
0      0     
    28 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    29 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    30 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
    31 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    32 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    33 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
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    34 4:ESOPHAGU   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      
0      0     
    35 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *0.833  0.167  0      0      0      0      0      0      0      
0      0     
    36 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *0.833  0.167  0      0      0      0      0      0      0      
0      0     
    37 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *0.833  0.167  0      0      0      0      0      0      0      
0      0     
    38 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
    39 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *0.833  0.167  0      0      0      0      0      0      0      
0      0     
    40 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *0.833  0.167  0      0      0      0      0      0      0      
0      0     
    41 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    42 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    43 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    44 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    45 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    46 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    47 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    48 5:GASTRIC  4:ESOPHAGU      +   0      0      0     *0.833  0.167  0      0      0      0      0      0      0      
0      0     
    49 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    50 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    51   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *0.5    0.5    0      0      0      0      0      0      
0     
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    52   6:GLIOMA   11:NSCLC      +   0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
    53   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    54   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    55   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    56   6:GLIOMA 14:PROSTAT      +   0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
    57   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    58   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    59   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    60   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
    61 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    62 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    63 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    64 7:HEPATOCE   6:GLIOMA      +   0      0      0      0      0     *0.5    0.5    0      0      0      0      0      0      
0     
    65 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    66 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    67 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    68 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    69 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    70 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    71 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    72 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
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    73 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    74 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    75 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    76 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    77 8:KIDNEY C 13:PANCREA      +   0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
    78 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    79 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    80 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
    81 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
    82 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
    83 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
    84 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
    85 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
    86 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
    87 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
    88 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
    89 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
    90 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
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    91 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
    92 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
    93 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
    94 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
    95 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
    96 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
    97 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
    98 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
    99 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
   100 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
   101   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   102   11:NSCLC   11:NSCLC          0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
   103   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   104   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   105   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   106   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   107   11:NSCLC   11:NSCLC          0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
   108   11:NSCLC   11:NSCLC          0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
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   109   11:NSCLC   11:NSCLC          0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
   110   11:NSCLC   11:NSCLC          0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
   111 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   112 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   113 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   114 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   115 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   116 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   117 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   118 12:OVARIAN 8:KIDNEY C      +   0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   119 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   120 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   121 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   122 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   123 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   124 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   125 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   126 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
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   127 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   128 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   129 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   130 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   131 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   132 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   133 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   134 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   135 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   136 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   137 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   138 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   139 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   140 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   141 1:BLADDER  9:LUNG SQU      +   0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
   142 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   143 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   144 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
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   145 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   146 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   147 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   148 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   149 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   150 1:BLADDER  1:BLADDER          *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   151 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
   152 2:BREAST C   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      
0      0     
   153 2:BREAST C 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   154 2:BREAST C 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   155 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
   156 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
   157 2:BREAST C 2:BREAST C          0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
   158 2:BREAST C 2:BREAST C          0     *0.667  0.333  0      0      0      0      0      0      0      0      0      
0      0     
   159 2:BREAST C 2:BREAST C          0     *0.667  0.333  0      0      0      0      0      0      0      0      0      
0      0     
   160 2:BREAST C 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   161 3:COLON CA   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      
0      0     
   162 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
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   163 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   164 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   165 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   166 3:COLON CA 4:ESOPHAGU      +   0      0      0     *1      0      0      0      0      0      0      0      0      0      
0     
   167 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   168 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   169 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   170 3:COLON CA 3:COLON CA          0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   171 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   172 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      
0      0     
   173 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      
0      0     
   174 4:ESOPHAGU   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      
0      0     
   175 4:ESOPHAGU 9:LUNG SQU      +   0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
   176 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   177 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   178 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   179 4:ESOPHAGU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   180 4:ESOPHAGU 4:ESOPHAGU          0      0      0     *1      0      0      0      0      0      0      0      0      
0      0     
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   181 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   182 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   183 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   184 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   185 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   186 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   187 5:GASTRIC  7:HEPATOCE      +   0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   188 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   189 5:GASTRIC  8:KIDNEY C      +   0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   190 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   191   6:GLIOMA   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
   192   6:GLIOMA   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
   193   6:GLIOMA   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
   194   6:GLIOMA 14:PROSTAT      +   0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   195   6:GLIOMA   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
   196   6:GLIOMA 14:PROSTAT      +   0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   197   6:GLIOMA   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
   198   6:GLIOMA 14:PROSTAT      +   0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
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   199   6:GLIOMA   6:GLIOMA          0      0      0      0      0     *1      0      0      0      0      0      0      0      0     
   200   6:GLIOMA 2:BREAST C      +   0     *1      0      0      0      0      0      0      0      0      0      0      0      
0     
   201 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   202 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   203 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   204 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   205 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   206 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   207 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   208 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   209 7:HEPATOCE 13:PANCREA      +   0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   210 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   211 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   212 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   213 8:KIDNEY C   6:GLIOMA      +   0      0      0      0      0     *0.5    0.5    0      0      0      0      0      0      
0     
   214 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   215 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   216 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
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   217 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   218 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   219 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   220 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   221 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
   222 9:LUNG SQU   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      
0      0     
   223 9:LUNG SQU 3:COLON CA      +   0      0     *1      0      0      0      0      0      0      0      0      0      0      
0     
   224 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
   225 9:LUNG SQU   6:GLIOMA      +   0      0      0      0      0     *1      0      0      0      0      0      0      0      
0     
   226 9:LUNG SQU 9:LUNG SQU          0      0      0      0      0      0      0      0     *1      0      0      0      0      
0     
   227 9:LUNG SQU 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   228 9:LUNG SQU 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   229 9:LUNG SQU 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   230 9:LUNG SQU 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   231 10:MELANOM 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      
0      0     
   232 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
   233 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
   234 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
156 
 
   235 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
   236 10:MELANOM   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      
0      0     
   237 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
   238 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
   239 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
   240 10:MELANOM 10:MELANOM          0.091  0      0      0      0      0      0      0      0     *0.909  0      0      
0      0     
   241   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   242   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   243   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   244   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   245   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   246   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   247   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   248   11:NSCLC   11:NSCLC          0      0      0      0      0      0.167  0      0      0      0     *0.833  0      0      
0     
   249   11:NSCLC   11:NSCLC          0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
   250   11:NSCLC   11:NSCLC          0      0      0      0.167  0      0      0      0      0      0     *0.833  0      0      
0     
   251 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
   252 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0      0      0      0      0      0     *1      0      
0     
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   253 12:OVARIAN   11:NSCLC      +   0      0      0      0      0      0.167  0      0      0      0     *0.833  0      
0      0     
   254 12:OVARIAN   11:NSCLC      +   0      0      0      0      0      0.167  0      0      0      0     *0.833  0      
0      0     
   255 12:OVARIAN 13:PANCREA      +   0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   256 12:OVARIAN 13:PANCREA      +   0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   257 12:OVARIAN 8:KIDNEY C      +   0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   258 12:OVARIAN 8:KIDNEY C      +   0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
   259 12:OVARIAN   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      
0      0     
   260 12:OVARIAN   11:NSCLC      +   0      0      0      0.167  0      0      0      0      0      0     *0.833  0      
0      0     
   261 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   262 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   263 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   264 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   265 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   266 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   267 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   268 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   269 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   270 13:PANCREA 8:KIDNEY C      +   0      0      0      0      0      0      0     *0.9    0      0      0      0.1    0      
0     
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   271 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   272 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   273 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   274 14:PROSTAT 13:PANCREA      +   0      0      0      0      0      0      0      0.091  0      0      0      0     
*0.909  0     
   275 14:PROSTAT   6:GLIOMA      +   0      0      0      0      0     *1      0      0      0      0      0      0      0      
0     
   276 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   277 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   278 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
   279 14:PROSTAT 1:BLADDER       +  *0.9    0.1    0      0      0      0      0      0      0      0      0      0      0      
0     
   280 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0.091  0      0      0      0      0      0      0     
*0.909 
 
=== Evaluation on test set === 
=== Summary === 
 
Correctly Classified Instances         222               79.2857 % 
Incorrectly Classified Instances        58               20.7143 % 
Kappa statistic                          0.7769 
Mean absolute error                      0.0357 
Root mean squared error                  0.1639 
Relative absolute error                 26.9091 % 
Root relative squared error             63.6456 % 
Total Number of Instances              280      
 
=== Detailed Accuracy By Class === 
 
               TP Rate   FP Rate   Precision   Recall  F-Measure   ROC Area  Class 
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                 0.9       0.031      0.692     0.9       0.783      0.955    BLADDER CANCER 
                 0.75      0.008      0.882     0.75      0.811      0.91     BREAST CARCINOMA 
                 0.85      0.031      0.68      0.85      0.756      0.933    COLON CARCINOMA 
                 0.6       0.008      0.857     0.6       0.706      0.832    ESOPHAGUS CARCINOMA 
                 0.85      0          1         0.85      0.919      0.949    GASTRIC CANCER 
                 0.45      0.015      0.692     0.45      0.545      0.804    GLIOMA 
                 0.9       0.004      0.947     0.9       0.923      0.973    HEPATOCELLULAR CARCINOMA 
                 0.9       0.019      0.783     0.9       0.837      0.959    KIDNEY CARCINOMA 
                 0.65      0.008      0.867     0.65      0.743      0.821    LUNG SQUAMOUS CELL CARCINOMA 
                 0.9       0.004      0.947     0.9       0.923      0.948    MELANOMA 
                 1         0.062      0.556     1         0.714      0.969    NSCLC 
                 0.55      0          1         0.55      0.71       0.834    OVARIAN CARCINOMA 
                 0.95      0.019      0.792     0.95      0.864      0.965    PANCREAS CARCINOMA 
                 0.85      0.015      0.81      0.85      0.829      0.917    PROSTATE CARCINOMA 
Weighted Avg.    0.793     0.016      0.822     0.793     0.79       0.912 
 
=== Confusion Matrix === 
 
  a  b  c  d  e  f  g  h  i  j  k  l  m  n   <-- classified as 
 18  0  0  0  0  0  0  0  1  1  0  0  0  0 |  a = BLADDER CANCER 
  2 15  2  0  0  0  0  0  0  0  1  0  0  0 |  b = BREAST CARCINOMA 
  0  1 17  1  0  0  0  0  0  0  1  0  0  0 |  c = COLON CARCINOMA 
  0  0  5 12  0  0  0  0  1  0  2  0  0  0 |  d = ESOPHAGUS CARCINOMA 
  0  0  0  1 17  0  1  1  0  0  0  0  0  0 |  e = GASTRIC CANCER 
  0  1  0  0  0  9  0  0  0  0  6  0  0  4 |  f = GLIOMA 
  0  0  0  0  0  1 18  0  0  0  0  0  1  0 |  g = HEPATOCELLULAR CARCINOMA 
  0  0  0  0  0  1  0 18  0  0  0  0  1  0 |  h = KIDNEY CARCINOMA 
  4  0  1  0  0  1  0  0 13  0  1  0  0  0 |  i = LUNG SQUAMOUS CELL CARCINOMA 
  1  0  0  0  0  0  0  0  0 18  1  0  0  0 |  j = MELANOMA 
  0  0  0  0  0  0  0  0  0  0 20  0  0  0 |  k = NSCLC 
  0  0  0  0  0  0  0  3  0  0  4 11  2  0 |  l = OVARIAN CARCINOMA 
  0  0  0  0  0  0  0  1  0  0  0  0 19  0 |  m = PANCREAS CARCINOMA 
  1  0  0  0  0  1  0  0  0  0  0  0  1 17 |  n = PROSTATE CARCINOMA 
 
=== Run information === 
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Scheme:weka.classifiers.rules.JRip -F 3 -N 2.0 -O 2 -S 1 
Relation:     TrainingData323SOLIDnoADENO48miR-weka.filters.unsupervised.attribute.Remove-R2-
3,7-11,13,15-16,18-23,26-29,31-32,34-36,40-45,47 
Instances:    140 
Attributes:   16 
              hsa-let-7e 
              hsa-miR-105* 
              hsa-miR-10a 
              hsa-miR-122 
              hsa-miR-145 
              hsa-miR-15b 
              hsa-miR-193b 
              hsa-miR-215 
              hsa-miR-218 
              hsa-miR-30c-1* 
              hsa-miR-330-5p 
              hsa-miR-34c-3p 
              hsa-miR-375 
              hsa-miR-383 
              hsa-miR-9 
              Class 
Test mode:evaluate on training data 
 
=== Classifier model (full training set) === 
 
JRIP rules: 
=========== 
 
(hsa-miR-383 <= 4.417) and (hsa-miR-30c-1* >= 4.024) and (hsa-miR-215 <= 5.322) => Class=LUNG 
SQUAMOUS CELL CARCINOMA (11.0/3.0) 
(hsa-miR-9 >= 8.487) => Class=GLIOMA (10.0/2.0) 
(hsa-miR-122 >= 11.89) => Class=HEPATOCELLULAR CARCINOMA (9.0/0.0) 
(hsa-miR-145 <= 3.852) and (hsa-let-7e >= 9.894) => Class=PROSTATE CARCINOMA (9.0/0.0) 
(hsa-miR-383 >= 9.519) => Class=MELANOMA (9.0/1.0) 
(hsa-miR-15b >= 8.367) and (hsa-miR-218 <= 4.893) => Class=BREAST CARCINOMA (8.0/1.0) 
(hsa-miR-145 >= 11.285) and (hsa-miR-383 >= 6.18) => Class=GASTRIC CANCER (8.0/0.0) 
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(hsa-miR-145 <= 7.731) and (hsa-miR-193b <= 8.717) => Class=NSCLC (9.0/1.0) 
(hsa-miR-330-5p >= 8.863) => Class=NSCLC (2.0/0.0) 
(hsa-miR-330-5p >= 7.761) and (hsa-miR-122 <= 7.731) => Class=BLADDER CANCER (4.0/0.0) 
(hsa-miR-218 <= 3.513) and (hsa-miR-10a <= 9.198) => Class=BLADDER CANCER (4.0/0.0) 
(hsa-miR-145 <= 9.173) and (hsa-miR-375 <= 8.103) => Class=OVARIAN CARCINOMA (8.0/1.0) 
(hsa-miR-330-5p <= 3.533) => Class=KIDNEY CARCINOMA (5.0/0.0) 
(hsa-miR-218 >= 7.41) => Class=PANCREAS CARCINOMA (12.0/2.0) 
(hsa-miR-383 >= 7.298) => Class=ESOPHAGUS CARCINOMA (11.0/3.0) 
 => Class=COLON CARCINOMA (21.0/12.0) 
 
Number of Rules : 16 
 
 
Time taken to build model: 0.11 seconds 
 
=== Predictions on training set === 
 
inst#,    actual, predicted, error, probability distribution 
     1 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     2 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     3 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     4 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     5 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     6 1:BLADDER  3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
     7 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     8 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     9 1:BLADDER  9:LUNG SQU      +   0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
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    10 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
    11 2:BREAST C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    12 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    13 2:BREAST C 9:LUNG SQU      +   0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    14 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    15 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    16 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    17 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    18 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    19 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    20 2:BREAST C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    21 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    22 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    23 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    24 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    25 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    26 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    27 3:COLON CA 4:ESOPHAGU      +   0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
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    28 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    29 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    30 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    31 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    32 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    33 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    34 4:ESOPHAGU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    35 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    36 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    37 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    38 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    39 4:ESOPHAGU   6:GLIOMA      +   0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    40 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    41 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    42 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    43 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    44 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    45 5:GASTRIC  3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
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    46 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    47 5:GASTRIC  3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    48 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    49 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    50 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    51   6:GLIOMA 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    52   6:GLIOMA 12:OVARIAN      +   0      0      0      0      0      0.125  0      0      0      0      0     *0.875  0      
0     
    53   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    54   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    55   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    56   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    57   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    58   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    59   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    60   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    61 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    62 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    63 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
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    64 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    65 7:HEPATOCE 2:BREAST C      +   0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    66 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    67 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    68 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    69 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    70 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    71 8:KIDNEY C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    72 8:KIDNEY C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    73 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
    74 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
    75 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
    76 8:KIDNEY C 13:PANCREA      +   0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
    77 8:KIDNEY C 13:PANCREA      +   0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
    78 8:KIDNEY C 10:MELANOM      +   0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    79 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
    80 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
    81 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
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    82 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    83 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    84 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    85 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    86 9:LUNG SQU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    87 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    88 9:LUNG SQU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    89 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    90 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    91 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    92 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    93 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    94 10:MELANOM 4:ESOPHAGU      +   0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    95 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    96 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    97 10:MELANOM   6:GLIOMA      +   0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    98 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    99 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
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   100 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
   101   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   102   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   103   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   104   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   105   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   106   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   107   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   108   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   109   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   110   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   111 12:OVARIAN 4:ESOPHAGU      +   0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
   112 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   113 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   114 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   115 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   116 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   117 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   118 12:OVARIAN 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
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   119 12:OVARIAN   11:NSCLC      +   0      0      0      0      0      0      0      0      0      0     *0.889  0.111  
0      0     
   120 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   121 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   122 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   123 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   124 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   125 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   126 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   127 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   128 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   129 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   130 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   131 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   132 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   133 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   134 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   135 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   136 14:PROSTAT 9:LUNG SQU      +   0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
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   137 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   138 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   139 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   140 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
 
=== Evaluation on training set === 
=== Summary === 
 
Correctly Classified Instances         114               81.4286 % 
Incorrectly Classified Instances        26               18.5714 % 
Kappa statistic                          0.8    
Mean absolute error                      0.0406 
Root mean squared error                  0.1425 
Relative absolute error                 30.6135 % 
Root relative squared error             55.3295 % 
Total Number of Instances              140      
 
=== Detailed Accuracy By Class === 
 
               TP Rate   FP Rate   Precision   Recall  F-Measure   ROC Area  Class 
                 0.8       0          1         0.8       0.889      0.981    BLADDER CANCER 
                 0.7       0.008      0.875     0.7       0.778      0.962    BREAST CARCINOMA 
                 0.9       0.092      0.429     0.9       0.581      0.945    COLON CARCINOMA 
                 0.8       0.023      0.727     0.8       0.762      0.968    ESOPHAGUS CARCINOMA 
                 0.8       0          1         0.8       0.889      0.985    GASTRIC CANCER 
                 0.8       0.015      0.8       0.8       0.8        0.975    GLIOMA 
                 0.9       0          1         0.9       0.947      0.997    HEPATOCELLULAR CARCINOMA 
                 0.5       0          1         0.5       0.667      0.939    KIDNEY CARCINOMA 
                 0.8       0.023      0.727     0.8       0.762      0.972    LUNG SQUAMOUS CELL CARCINOMA 
                 0.8       0.008      0.889     0.8       0.842      0.981    MELANOMA 
                 1         0.008      0.909     1         0.952      0.997    NSCLC 
                 0.7       0.008      0.875     0.7       0.778      0.96     OVARIAN CARCINOMA 
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                 1         0.015      0.833     1         0.909      0.992    PANCREAS CARCINOMA 
                 0.9       0          1         0.9       0.947      0.996    PROSTATE CARCINOMA 
Weighted Avg.    0.814     0.014      0.862     0.814     0.822      0.975 
 
=== Confusion Matrix === 
 
  a  b  c  d  e  f  g  h  i  j  k  l  m  n   <-- classified as 
  8  0  1  0  0  0  0  0  1  0  0  0  0  0 |  a = BLADDER CANCER 
  0  7  2  0  0  0  0  0  1  0  0  0  0  0 |  b = BREAST CARCINOMA 
  0  0  9  1  0  0  0  0  0  0  0  0  0  0 |  c = COLON CARCINOMA 
  0  0  1  8  0  1  0  0  0  0  0  0  0  0 |  d = ESOPHAGUS CARCINOMA 
  0  0  2  0  8  0  0  0  0  0  0  0  0  0 |  e = GASTRIC CANCER 
  0  0  1  0  0  8  0  0  0  0  0  1  0  0 |  f = GLIOMA 
  0  1  0  0  0  0  9  0  0  0  0  0  0  0 |  g = HEPATOCELLULAR CARCINOMA 
  0  0  2  0  0  0  0  5  0  1  0  0  2  0 |  h = KIDNEY CARCINOMA 
  0  0  2  0  0  0  0  0  8  0  0  0  0  0 |  i = LUNG SQUAMOUS CELL CARCINOMA 
  0  0  0  1  0  1  0  0  0  8  0  0  0  0 |  j = MELANOMA 
  0  0  0  0  0  0  0  0  0  0 10  0  0  0 |  k = NSCLC 
  0  0  1  1  0  0  0  0  0  0  1  7  0  0 |  l = OVARIAN CARCINOMA 
  0  0  0  0  0  0  0  0  0  0  0  0 10  0 |  m = PANCREAS CARCINOMA 
  0  0  0  0  0  0  0  0  1  0  0  0  0  9 |  n = PROSTATE CARCINOMA 
=== Run information === 
 
Scheme:weka.classifiers.rules.JRip -F 3 -N 2.0 -O 2 -S 1 
Relation:     TrainingData323SOLIDnoADENO48miR-weka.filters.unsupervised.attribute.Remove-R2-
3,7-11,13,15-16,18-23,26-29,31-32,34-36,40-45,47 
Instances:    140 
Attributes:   16 
              hsa-let-7e 
              hsa-miR-105* 
              hsa-miR-10a 
              hsa-miR-122 
              hsa-miR-145 
              hsa-miR-15b 
              hsa-miR-193b 
              hsa-miR-215 
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              hsa-miR-218 
              hsa-miR-30c-1* 
              hsa-miR-330-5p 
              hsa-miR-34c-3p 
              hsa-miR-375 
              hsa-miR-383 
              hsa-miR-9 
              Class 
Test mode:user supplied test set: size unknown (reading incrementally) 
 
=== Classifier model (full training set) === 
 
JRIP rules: 
=========== 
 
(hsa-miR-383 <= 4.417) and (hsa-miR-30c-1* >= 4.024) and (hsa-miR-215 <= 5.322) => Class=LUNG 
SQUAMOUS CELL CARCINOMA (11.0/3.0) 
(hsa-miR-9 >= 8.487) => Class=GLIOMA (10.0/2.0) 
(hsa-miR-122 >= 11.89) => Class=HEPATOCELLULAR CARCINOMA (9.0/0.0) 
(hsa-miR-145 <= 3.852) and (hsa-let-7e >= 9.894) => Class=PROSTATE CARCINOMA (9.0/0.0) 
(hsa-miR-383 >= 9.519) => Class=MELANOMA (9.0/1.0) 
(hsa-miR-15b >= 8.367) and (hsa-miR-218 <= 4.893) => Class=BREAST CARCINOMA (8.0/1.0) 
(hsa-miR-145 >= 11.285) and (hsa-miR-383 >= 6.18) => Class=GASTRIC CANCER (8.0/0.0) 
(hsa-miR-145 <= 7.731) and (hsa-miR-193b <= 8.717) => Class=NSCLC (9.0/1.0) 
(hsa-miR-330-5p >= 8.863) => Class=NSCLC (2.0/0.0) 
(hsa-miR-330-5p >= 7.761) and (hsa-miR-122 <= 7.731) => Class=BLADDER CANCER (4.0/0.0) 
(hsa-miR-218 <= 3.513) and (hsa-miR-10a <= 9.198) => Class=BLADDER CANCER (4.0/0.0) 
(hsa-miR-145 <= 9.173) and (hsa-miR-375 <= 8.103) => Class=OVARIAN CARCINOMA (8.0/1.0) 
(hsa-miR-330-5p <= 3.533) => Class=KIDNEY CARCINOMA (5.0/0.0) 
(hsa-miR-218 >= 7.41) => Class=PANCREAS CARCINOMA (12.0/2.0) 
(hsa-miR-383 >= 7.298) => Class=ESOPHAGUS CARCINOMA (11.0/3.0) 
 => Class=COLON CARCINOMA (21.0/12.0) 
 
Number of Rules : 16 
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Time taken to build model: 0.09 seconds 
 
=== Predictions on test split === 
 
inst#,    actual, predicted, error, probability distribution 
     1 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     2 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     3 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     4 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     5 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     6 1:BLADDER  3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
     7 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     8 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
     9 1:BLADDER  9:LUNG SQU      +   0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    10 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
    11 2:BREAST C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    12 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    13 2:BREAST C 9:LUNG SQU      +   0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    14 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    15 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
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    16 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    17 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    18 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    19 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    20 2:BREAST C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    21 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    22 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    23 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    24 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    25 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    26 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    27 3:COLON CA 4:ESOPHAGU      +   0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    28 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    29 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    30 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    31 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    32 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    33 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
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    34 4:ESOPHAGU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    35 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    36 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    37 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    38 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    39 4:ESOPHAGU   6:GLIOMA      +   0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    40 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    41 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    42 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    43 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    44 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    45 5:GASTRIC  3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    46 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    47 5:GASTRIC  3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    48 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    49 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    50 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
    51   6:GLIOMA 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
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    52   6:GLIOMA 12:OVARIAN      +   0      0      0      0      0      0.125  0      0      0      0      0     *0.875  0      
0     
    53   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    54   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    55   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    56   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    57   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    58   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    59   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    60   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    61 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    62 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    63 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    64 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    65 7:HEPATOCE 2:BREAST C      +   0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
    66 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    67 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    68 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    69 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
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    70 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
    71 8:KIDNEY C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    72 8:KIDNEY C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    73 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
    74 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
    75 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
    76 8:KIDNEY C 13:PANCREA      +   0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
    77 8:KIDNEY C 13:PANCREA      +   0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
    78 8:KIDNEY C 10:MELANOM      +   0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    79 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
    80 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
    81 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    82 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    83 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    84 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    85 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    86 9:LUNG SQU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    87 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
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    88 9:LUNG SQU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
    89 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    90 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
    91 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    92 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    93 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    94 10:MELANOM 4:ESOPHAGU      +   0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
    95 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    96 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    97 10:MELANOM   6:GLIOMA      +   0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
    98 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
    99 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
   100 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
   101   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   102   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   103   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   104   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   105   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
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   106   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   107   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   108   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   109   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   110   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   111 12:OVARIAN 4:ESOPHAGU      +   0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
   112 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   113 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   114 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   115 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   116 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   117 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   118 12:OVARIAN 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   119 12:OVARIAN   11:NSCLC      +   0      0      0      0      0      0      0      0      0      0     *0.889  0.111  
0      0     
   120 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   121 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   122 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   123 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   124 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
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   125 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   126 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   127 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   128 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   129 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   130 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   131 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   132 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   133 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   134 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   135 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   136 14:PROSTAT 9:LUNG SQU      +   0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
   137 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   138 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   139 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   140 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   141 1:BLADDER    11:NSCLC      +   0      0      0      0      0      0      0      0      0      0     *1      0      0      
0     
   142 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
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   143 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   144 1:BLADDER  3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   145 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   146 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   147 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   148 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   149 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   150 1:BLADDER  1:BLADDER          *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   151 2:BREAST C 1:BLADDER       +  *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   152 2:BREAST C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   153 2:BREAST C 9:LUNG SQU      +   0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
   154 2:BREAST C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   155 2:BREAST C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   156 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
   157 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
   158 2:BREAST C 2:BREAST C          0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
   159 2:BREAST C 12:OVARIAN      +   0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   160 2:BREAST C 12:OVARIAN      +   0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
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   161 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   162 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   163 3:COLON CA 1:BLADDER       +  *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   164 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   165 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   166 3:COLON CA   11:NSCLC      +   0      0      0      0      0      0      0      0      0      0     *1      0      0      
0     
   167 3:COLON CA 7:HEPATOCE      +   0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   168 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   169 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   170 3:COLON CA 3:COLON CA          0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   171 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
   172 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
   173 4:ESOPHAGU 1:BLADDER       +  *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   174 4:ESOPHAGU 5:GASTRIC       +   0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   175 4:ESOPHAGU 5:GASTRIC       +   0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   176 4:ESOPHAGU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   177 4:ESOPHAGU 4:ESOPHAGU          0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
   178 4:ESOPHAGU 5:GASTRIC       +   0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
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   179 4:ESOPHAGU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   180 4:ESOPHAGU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   181 5:GASTRIC  3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   182 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   183 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   184 5:GASTRIC  10:MELANOM      +   0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
   185 5:GASTRIC  4:ESOPHAGU      +   0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
   186 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   187 5:GASTRIC  8:KIDNEY C      +   0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   188 5:GASTRIC  8:KIDNEY C      +   0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   189 5:GASTRIC  8:KIDNEY C      +   0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   190 5:GASTRIC  5:GASTRIC           0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   191   6:GLIOMA   11:NSCLC      +   0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   192   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
   193   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
   194   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
   195   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
   196   6:GLIOMA 2:BREAST C      +   0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
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   197   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
   198   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
   199   6:GLIOMA   6:GLIOMA          0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
   200   6:GLIOMA 2:BREAST C      +   0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
   201 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   202 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   203 7:HEPATOCE 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   204 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   205 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   206 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   207 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   208 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   209 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   210 7:HEPATOCE 7:HEPATOCE          0      0      0      0      0      0     *1      0      0      0      0      0      0      
0     
   211 8:KIDNEY C 5:GASTRIC       +   0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   212 8:KIDNEY C 13:PANCREA      +   0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   213 8:KIDNEY C 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   214 8:KIDNEY C   6:GLIOMA      +   0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
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   215 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   216 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   217 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   218 8:KIDNEY C   6:GLIOMA      +   0      0      0      0.1    0     *0.8    0      0      0      0.1    0      0      0      
0     
   219 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   220 8:KIDNEY C 8:KIDNEY C          0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   221 9:LUNG SQU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   222 9:LUNG SQU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   223 9:LUNG SQU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   224 9:LUNG SQU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   225 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
   226 9:LUNG SQU 9:LUNG SQU          0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
   227 9:LUNG SQU 1:BLADDER       +  *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   228 9:LUNG SQU 1:BLADDER       +  *1      0      0      0      0      0      0      0      0      0      0      0      0      
0     
   229 9:LUNG SQU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   230 9:LUNG SQU 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
   231 10:MELANOM 12:OVARIAN      +   0      0      0      0      0      0.125  0      0      0      0      0     
*0.875  0      0     
   232 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
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   233 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
   234 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
   235 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
   236 10:MELANOM 4:ESOPHAGU      +   0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
   237 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
   238 10:MELANOM   11:NSCLC      +   0      0      0      0      0      0      0      0      0      0     *0.889  0.111  
0      0     
   239 10:MELANOM 10:MELANOM          0      0      0      0      0      0      0      0.111  0     *0.889  0      0      
0      0     
   240 10:MELANOM 4:ESOPHAGU      +   0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
   241   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   242   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   243   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   244   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   245   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   246   11:NSCLC 13:PANCREA      +   0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   247   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   248   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
   249   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *1      0      0      0     
   250   11:NSCLC   11:NSCLC          0      0      0      0      0      0      0      0      0      0     *0.889  0.111  0      
0     
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   251 12:OVARIAN 4:ESOPHAGU      +   0      0      0.091 *0.727  0      0      0      0      0      0.091  0      
0.091  0      0     
   252 12:OVARIAN 9:LUNG SQU      +   0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
   253 12:OVARIAN 9:LUNG SQU      +   0.091  0.091  0      0      0      0      0      0     *0.727  0      0      0      
0      0.091 
   254 12:OVARIAN 12:OVARIAN          0      0      0      0      0      0.125  0      0      0      0      0     *0.875  
0      0     
   255 12:OVARIAN 13:PANCREA      +   0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   256 12:OVARIAN 8:KIDNEY C      +   0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   257 12:OVARIAN 8:KIDNEY C      +   0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   258 12:OVARIAN 5:GASTRIC       +   0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   259 12:OVARIAN 5:GASTRIC       +   0      0      0      0     *1      0      0      0      0      0      0      0      0      
0     
   260 12:OVARIAN 8:KIDNEY C      +   0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   261 13:PANCREA   11:NSCLC      +   0      0      0      0      0      0      0      0      0      0     *0.889  0.111  
0      0     
   262 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   263 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   264 13:PANCREA 8:KIDNEY C      +   0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   265 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   266 13:PANCREA 8:KIDNEY C      +   0      0      0      0      0      0      0     *1      0      0      0      0      0      
0     
   267 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   268 13:PANCREA 3:COLON CA      +   0.048  0.095 *0.429  0.048  0.095  0.048  0      0.095  0.095  0      
0      0.048  0      0     
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   269 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   270 13:PANCREA 13:PANCREA          0      0      0      0      0      0      0      0.167  0      0      0      0     
*0.833  0     
   271 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   272 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   273 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   274 14:PROSTAT   11:NSCLC      +   0      0      0      0      0      0      0      0      0      0     *0.889  0.111  
0      0     
   275 14:PROSTAT 2:BREAST C      +   0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
   276 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   277 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   278 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   279 14:PROSTAT 14:PROSTAT          0      0      0      0      0      0      0      0      0      0      0      0      0     
*1     
   280 14:PROSTAT 2:BREAST C      +   0     *0.875  0      0      0      0      0.125  0      0      0      0      0      
0      0     
 
=== Evaluation on test set === 
=== Summary === 
 
Correctly Classified Instances         191               68.2143 % 
Incorrectly Classified Instances        89               31.7857 % 
Kappa statistic                          0.6577 
Mean absolute error                      0.0566 
Root mean squared error                  0.1932 
Relative absolute error                 42.634  % 
Root relative squared error             75.0182 % 
Total Number of Instances              280      
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=== Detailed Accuracy By Class === 
               TP Rate   FP Rate   Precision   Recall  F-Measure   ROC Area  Class 
                 0.8       0.019      0.762     0.8       0.78       0.943    BLADDER CANCER 
                 0.5       0.019      0.667     0.5       0.571      0.859    BREAST CARCINOMA 
                 0.8       0.112      0.356     0.8       0.492      0.86     COLON CARCINOMA 
                 0.55      0.027      0.611     0.55      0.579      0.829    ESOPHAGUS CARCINOMA 
                 0.6       0.023      0.667     0.6       0.632      0.829    GASTRIC CANCER 
                 0.75      0.015      0.789     0.75      0.769      0.893    GLIOMA 
                 0.9       0.004      0.947     0.9       0.923      0.97     HEPATOCELLULAR CARCINOMA 
                 0.5       0.031      0.556     0.5       0.526      0.841    KIDNEY CARCINOMA 
                 0.5       0.023      0.625     0.5       0.556      0.898    LUNG SQUAMOUS CELL CARCINOMA 
                 0.7       0.008      0.875     0.7       0.778      0.923    MELANOMA 
                 0.95      0.027      0.731     0.95      0.826      0.96     NSCLC 
                 0.4       0.015      0.667     0.4       0.5        0.705    OVARIAN CARCINOMA 
                 0.8       0.019      0.762     0.8       0.78       0.89     PANCREAS CARCINOMA 
                 0.8       0          1         0.8       0.889      0.919    PROSTATE CARCINOMA 
Weighted Avg.    0.682     0.024      0.715     0.682     0.686      0.88  
 
=== Confusion Matrix === 
  a  b  c  d  e  f  g  h  i  j  k  l  m  n   <-- classified as 
 16  0  2  0  0  0  0  0  1  0  1  0  0  0 |  a = BLADDER CANCER 
  1 10  5  0  0  0  0  0  2  0  0  2  0  0 |  b = BREAST CARCINOMA 
  1  0 16  1  0  0  1  0  0  0  1  0  0  0 |  c = COLON CARCINOMA 
  1  0  4 11  3  1  0  0  0  0  0  0  0  0 |  d = ESOPHAGUS CARCINOMA 
  0  0  3  1 12  0  0  3  0  1  0  0  0  0 |  e = GASTRIC CANCER 
  0  2  1  0  0 15  0  0  0  0  1  1  0  0 |  f = GLIOMA 
  0  1  1  0  0  0 18  0  0  0  0  0  0  0 |  g = HEPATOCELLULAR CARCINOMA 
  0  0  3  0  1  2  0 10  0  1  0  0  3  0 |  h = KIDNEY CARCINOMA 
  2  0  8  0  0  0  0  0 10  0  0  0  0  0 |  i = LUNG SQUAMOUS CELL CARCINOMA 
  0  0  0  3  0  1  0  0  0 14  1  1  0  0 |  j = MELANOMA 
  0  0  0  0  0  0  0  0  0  0 19  0  1  0 |  k = NSCLC 
  0  0  1  2  2  0  0  3  2  0  1  8  1  0 |  l = OVARIAN CARCINOMA 
  0  0  1  0  0  0  0  2  0  0  1  0 16  0 |  m = PANCREAS CARCINOMA 
  0  2  0  0  0  0  0  0  1  0  1  0  0 16 |  n = PROSTATE CARCINOMA 
